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Abstract
Objective: This pilot study aimed to advance our current understanding of the role of 
biological processes in the development of specific neuropsychiatric complications in 
HIV/AIDS. In particular, this project explored whether elevated systemic indicators of 
immune system (i.e., IL-6, TNF-alpha, and neopterin) and hypothalamic-pituitary adrenal 
axis (HPA) activation (i.e., cortisol) were associated with commonly reported clinical 
symptoms of cognitive impairment, fatigue, and depression.
Method: Thirty-one HAART-nalve adults (i.e., no past or current use of antiretroviral 
medications) adults with HIV infection completed subjective symptom questionnaires 
and neuropsychological tests. Blood samples were obtained and processed at three 
separate laboratories. One-tailed Spearman correlations were used to examine the 
relations between serum concentrations of immune and HP A factors, cognitive 
impairments (learning efficiency, attention/working memory, and psychomotor 
processing speed), and subjective symptoms (fatigue, depression, cognitive complaints, 
and general illnesses).
Results: Neuropsychological impairment was not associated with the levels of biological 
markers. Depressive symptoms were, however, modestly associated with elevated IL-6 
mRNA expression (rs = 0.40, p  < .05) even after removing the influences of fatigue, total 
cognitive complaints, and illness symptoms (pr = 0.39, p  < .05). Elevated serum 
neopterin was strongly associated with depressive symptoms in individuals taking 
antidepressants (rs = 0.83,/? < .001), though the association was nullified in the group not 
taking any antidepressants (r„ = -0.25, p  > .05). More specifically, mean neopterin levels 
were higher in the depressed as compared with non-depressed group but only for those 
individuals taking antidepressants [F(l, 11) = 45.66,/? < .001].
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Conclusion: Increased subjective symptoms, especially depression, may be associated 
with elevated immune activation (i.e., higher levels of IL-6 mRNA and neopterin) in 
some individuals with HIV infection. While antidepressants may - exert 
immunosuppressive effects in treatment-responsive individuals, treatment-resistant 
individuals may continue to have both elevated depressive symptoms and neopterin 
levels despite presumably therapeutic doses of antidepressants. Although replication in a 
larger sample is needed, these preliminary findings suggest that systemic biological 
markers (especially neopterin) may be useful in differentiating individuals at greater risk 
o f developing chronic, debilitating depression. Implementation of alternative 
interventions may be necessary to alleviate depressive symptoms in this selective group 
and ultimately improve their quality of life.
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Since the human immunodeficiency virus (HIV) was identified as the causative 
agent for Acquired Immunodeficiency Syndrome (AIDS) in 1984, extensive research has 
been aimed at decelerating the worldwide spread of this devastating and life-threatening 
disease (Gallo et al., 1984). Initial investigations primarily centred around delineating the 
pathogenesis of HIV in attempt to develop drug therapies that interfere with the viral 
invasion and replication process. Combination highly active antiretroviral therapy 
(HAART) agents have proven effective at slowing disease progression (Carpenter et al., 
2000; Chaisson, 1998; Sendi, Bucher, Craig, Pfluger, & Battegay, 1999), though 
considerable variability in the rate of progression and clinical course of HIV infection 
still exists (Bouwman et al., 1998; Weber, 2001). New issues in clinical management 
have concurrently emerged with medical advancements and prolonged life expectancy. 
Individuals with HIV infection frequently report that the presence of cognitive 
impairments, somatic symptoms (especially chronic fatigue), and/or psychiatric 
difficulties adversely impacts their activities of daily living and quality of life. The causes 
and pathological processes underlying these symptoms in HIV/AIDS remains unclear. 
More multidisciplinary research is needed to identify specific factors (both biological and 
psychosocial) that explain some of the variability in clinical manifestations and predict 
at-risk individuals suitable for early interventions aimed at managing clinical symptoms 
and improving quality of life.
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Recent work in the area of psychoneuroimmunology highlights the need to 
consider the role biological processes play in mediating somatic, cognitive, and 
psychological symptoms in various illnesses. Although the significance of cytokine and 
hypothalamic-pituitary-adrenal (HPA) dysregulation in the neuropathogenesis of HIV has 
been described at a cellular mechanistic level (e.g., Brooke & Sapolsky, 2000; 
Gendelman, Lipton, Tardieu, Bukrinksy, & Nottet et al., 1994; Goodkin, Baldewicz, 
Wilkie, Tyll, & Shapshak, 2001; Kumar, Kumar, Waldrop, Antoni, & Eisdorfer, 2003), 
generalization of these findings to the broader clinical level is not readily apparent. To 
date, studies have generally focused on determining systemic (e.g., CD4 cell count, viral 
load, and cytokine) or central nervous system (CNS) (e.g., levels of HIV gpl20 viral 
proteins or neurotoxin production) biological markers of global levels of neurological 
functioning and disease progression in HIV/AIDS (e.g., Brookes & Sapolsky, 2000; 
Childs et al., 1999; Dal Pan et al., 1998; Griffin, McArthur, & Comblath, 1991; Ryan et 
al., 2001). Various psychosocial risk factors have also been related to overall disease 
progression in HIV and the development of HIV-related medical symptoms, though more 
research is needed to delineate the immunological and neuroendocrine mechanisms 
suspected of influencing this relationship (e.g., Balbin, Ironson, & Solomon, 1999; Cole, 
Kemeny, Fahey, Zack, & Naliboff, 2003; Kemeny, 2003). A paucity of literature still 
exists on the pathophysiology underlying the manifestation of specific neuropsychiatric 
complications in HIV/AIDS.
This exploratory study was designed to expand upon these previous studies by 
investigating the potential link between systemic biological markers (i.e., cortisol, IL-6, 
TNF-alpha, and neopterin) and the presence of specific clinical symptoms in adults with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
HIV/AIDS: cognitive impairments (i.e., attention and working memory, learning 
efficiency, and psychomotor/processing speed), fatigue, and depression. In the following 
sections, current literature providing the rationale for this pilot project will be outlined in 
more detail. First, the prevalence, functional implications, and potential relations between 
cognitive, somatic, and depressive symptoms will be reviewed. Next, a brief overview of 
the physiological and behavioural changes associated with activation of immune- 
endocrine-neurotransmitter pathways will be provided. The brain-behavioural 
consequences of dysregulation of this biological pathway documented in previous studies 
of healthy controls, other medical illnesses, and mood disorders will be described. Then, 
possible biological mechanisms contributing to brain-behaviour dysfunction in HIV 
infection will be reviewed at systems, cellular, and molecular levels. Finally, the goals 
and hypotheses of the present study will be outlined.
Prevalence andfunctional impact o f cognitive symptoms in HIV/AIDS
Self-reports of cognitive symptoms, occurring in about 40 to 50% of adults with 
HIV infection, commonly include slowed thinking, reduced attention span, increased 
distractibility, forgetfulness, difficulty at simultaneously completing more than one task, 
and blocking on words (Gibbs, Andrewes, Szmukler, Mulhall, & Bowden, 1990; Mehta 
et al., 1996). A similar proportion of individuals demonstrate cognitive impairments on 
neuropsychological tests, with the prevalence estimated to increase with advancing 
disease stage from about 30% of asymptomatic individuals to 56% of individuals 
diagnosed with AIDS (Bomstein et al., 1993; Heaton et al., 1995; White et al., 1995). 
Cognitive impairments can range from milder difficulties primarily seen in areas of 
attention and working memory, verbal fluency, learning efficiency, and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
psychomotor/processing speed (MCMD: HIV-associated minor cognitive/motor disorder) 
to profound dementia (HAD: HIV-associated dementia complex) (Janssen et al., 1991). 
Despite advances in HAART medication, HAD continues to develop in about 15% of 
individuals with AIDS (McArthur, Sacktor, & Seines, 1999). HAD resembles a 
subcortical pattern of dysfunction characterized by slowed cognitive processing, impaired 
recall of information, problems with attention/concentration, motor disturbances (e.g., 
slowing, unsteady gait, tremor, and leg weakness) and behavioural changes (e.g., apathy, 
irritability, loss of libido, and social withdrawal).
These cognitive difficulties can adversely affect everyday functioning to varying 
degrees. Studies have documented associations between cognitive impairments in 
individuals with HIV infection and poorer quality of life (Kaplan et al., 1995; Tozzi et al., 
2004), higher rates of unemployment and decreased work efficiency for those still 
employed (Albert et al., 1995; Benedict, Mezhir, Walsh, & Hewitt, 2000; Heaton et al., 
1996; Heaton et al., 1994; Rabkin, McElhiney, Ferrando, VanGorp & Lin, 2004), 
problems with medication adherence (Albert et al., 1998), and higher risk for mortality 
(Ellis et al., 1997; Mayeux et al., 1993; Sacktor et al., 1996; Wilkie et al., 1998). 
Recently, Heaton et al. (2004) reported an association between neuropsychological 
impairment and poorer performance on functional measures similar to everyday tasks 
(e.g., shopping, cooking, finances, medication management, and vocational abilities).
In summary, cognitive impairments remain prevalent despite advancements in 
antiretroviral drug therapies and these symptoms can negatively impact quality of life for 
individuals with HIV/AIDS.
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Prevalence and functional impact o f chronic fatigue and depression in HIV/AIDS
Fatigue and mood disturbance (especially depression and anxiety) are often 
present in many individuals with chronic illnesses, and are identified as the most 
challenging and debilitating symptoms to manage (e.g., Barroso et al., 2002; Denburg, 
Carbotte, & Denburg, 1997; Swain, 2000). Chronic fatigue is the most frequently 
reported symptom of patients with HIV and their health care providers, with estimates 
ranging from about 20% of asymptomatic individuals with HIV infection to about 40% of 
adults diagnosed with AIDS (Ferrando et al., 1998; Justice, Rabeneck, Hays, Wu, & 
Bozzette, 1999). Depression and anxiety are also prevalent in individuals with HIV, with 
estimates ranging from about 5 to 25% (Ciesla & Roberts, 2001; Grant & Atkinson, 
1990). Although depressive symptoms and fatigue are often highly correlated (e.g., 
Kalichman, Sikkema, & Somlai, 1995; O’Dell, Meighen, & Riggs, 1996; Perkins et al.,
1995), fatigue may remain in some individuals even after the alleviation of depressive 
symptoms (Ferrando et al., 1998). Fatigue and depression in adults with HIV have been 
associated with poorer quality of life and greater functional limitations, including poorer 
physical functioning, disability status, and difficulties maintaining employment (e.g., 
Cleary et al., 1993; Ferrando et al., 1998; Fleishman & Crystal, 1998; Justice et al., 1999; 
Rabkin et al., 2004).
In summary, many individuals with HIV suffer from psychiatric conditions 
(especially depressed mood) and chronic fatigue. These debilitating symptoms can affect 
their daily functioning and consequently their overall satisfaction with life.
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Contribution of multiple factors to the manifestation o f these symptoms
Given that these symptoms adversely affect quality of life, more attention needs 
to be directed toward investigating specific factors that may account for the variability in 
clinical manifestations across individuals with HIV/AIDS.
Cognitive symptoms. A series of ongoing studies conducted at S t  Michael’s 
Hospital within the Neurobehavioural Research Unit have aimed to clarify the source and 
clinical significance of cognitive symptoms in individuals with HIV infection by 
quantifying the independent contributions of various factors: (a) depressive symptoms; 
(b) brain functioning (as measured by neuropsychological test performance); (c) medical 
symptoms; and (d) fatigue. Multiple linear regressions and confirmatory factor analytic 
approaches have been employed to examine the relations between these symptoms. The 
following findings are summarized in Figure 1.
Depressive symptoms have consistently accounted for the majority o f the variance 
across various domains of self-reported cognitive symptoms (e.g., memory, language, 
sensory-motor, and executive problems) (Bassel, Rourke, Halman, & Smith, 2002; 
Rourke et al., 1999a and 1999b). Other studies have similarly found that depressive 
symptoms are moderately correlated with subjective cognitive difficulties in adults with 
HIV/AIDS (e.g., Beason-Hazen, Nasrallah, & Bomstein, 1994; Hinkin et al., 1996; 
Mapou et al., 1993; Moore et al., 1997; van Gorp et al., 1991; Wilkins et al., 1991).
A recent structural equation modeling study using a sample o f 160 adults with 
HIV infection showed that depression and medical symptoms were highly correlated. 
Both of these symptoms were also independently associated with overall cognitive 
symptoms (Carter, Rourke, Murji, Shore, & Rourke, 2003). Millikin, Rourke, Halman,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and Power (2003) also found that fatigue, even after statistically controlling for 
depressive symptoms, was associated with subjective cognitive symptoms in a group of 
68 men with HIV infection.
Some studies using multiple regressions analyses have also found that 
performance on neuropsychological tests, in particular complex psychomotor efficiency 
and working memory measures, independently accounted for a significant proportion of 
the variance across cognitive symptom domains even after the large influence of 
depression was removed (Bassel et al., 2002; Rourke et al., 1999a). Carter et al. (2003) 
similarly showed that neuropsychological performance was independently associated 
with cognitive symptoms, though not correlated with depression and medical symptoms. 
While some studies have supported this finding (e.g., Beason-Hazen et al., 1994; Lopez, 
Wess, Sanchez, Dew, & Becker, 1998; Mapou et al., 1993; Poutianinen & Elovaara,
1996), others have failed to obtain an association between self-reported cognitive 
symptoms and neuropsychological functioning (e.g., Hinkin et al., 1996; Moore et al., 
1997; van Gorp et al., 1991). The discrepant findings in the literature may be attributable, 
at least in part, to variable sample sizes, the breadth and type of cognitive symptoms 
tapped by questionnaires, and the different domains of neuropsychological functions 
measured.
Somatic and depressive symptoms. Disruption of physiological processes 
associated with the invasion and replication of the HIV virus likely contributes to the 
manifestation of some constitutional symptoms (Fell et al., 1993). Fluctuations in mood, 
energy level, appetite, and sleep patterns may also arise from prolonged exposure to 
stressful events or problems with adjusting and coping to life circumstances. Individuals
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
with HIV often experience significant psychosocial stressors throughout the course of 
their chronic illness, especially at transition points (e.g., discovery of seropositive status, 
initiation of HAART medications, or diagnosis of AIDS). Longitudinal studies have 
identified associations between certain psychosocial characteristics (e.g., stressful life 
events, denial/avoidance coping style, chronic depression, bereavement, and social 
isolation) and accelerated disease progression (e.g., Balbin, Ironson, & Solomon, 1999; 
Cole, Kemeny, Fahey, Zack, & Naliboff, 2003; Kemeny, 2003). Interestingly, some of 
these studies have also documented accompanying immunological and endocrine changes 
that may mediate the relation between psychosocial factors and disease progression. For 
example, Reed, Kemeny, Taylor, and Visscher (1999) noted that individuals with 
negative expectancies about their prognosis who recently experienced the death of a close 
friend to AIDS showed increased risk of developing HIV-related somatic symptoms over 
the next 2.5 to 3.5 years and an accelerated rate of mortality. Declines in CD4 T cell 
counts and elevations in serum markers of immune activation were observed to 
accompany this deterioration.
Moreover, a series of studies from the Behavioural Medicine Program at the 
University of Miami have demonstrated that interventions geared toward managing stress 
and developing positive coping strategies in individuals with HIV led to improvements in 
mood along with alterations in neuroendocrine functioning and immunological status 
(e.g., Antoni, 2003; Antoni et al., 1991; Antoni et al., 2000). These studies suggest that a 
better understanding of the interaction between psychological and physiological factors 
may be pivotal to managing depression and fatigue in individuals with HIV infection.
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Biologicalfactors may mediate symptom manifestation: “Illness behaviour”
While depression, fatigue, medical symptoms, and neuropsychological measures 
of brain functioning are associated with the presence of self-reported cognitive symptoms 
in some individuals with HIV/AIDS (see Figure 1), a significant proportion of the 
variability in clinical manifestation remains unexplained. A growing body of evidence 
within the field of psychoneuroimmunology suggests that systemic alterations in 
biological processes may mediate some of the somatic, mood, and cognitive changes seen 
in various immune-based illnesses. The regulation of biological activities is linked by 
common molecules (cytokines and hormones) and the distribution of their receptors 
throughout the body. These biological signals act on different tissues, including regions 
of the brain, to initiate and terminate different physiological and behavioural responses. 
Functions of the hippocampus, hypothalamus, basal ganglia, and prefrontal cortex 
connections may be particularly sensitive to fluctuations in cortisol or proinflammatory 
cytokines due to the high density of receptors located within these brain regions (e.g., 
Alderson & Novak, 2002; Bethea, Chung, Sapracio, Gillespie, & Benveniste, 1992; 
Heffelfinger & Newcomer, 2001; Lin, Amaral, Brosnan, & Lee, 1998; Rothwell & 
Luheshi, 1994). Recent investigations have demonstrated that cytokines can affect neural 
functioning both locally by their direct presence in brain tissue and systemically through 
stimulation of cranial nerves and crossing the blood-brain barrier at designated areas (for 
review see Kronfol & Remick, 2000; Maier, Goehler, Fleshner, & Watkins, 1998; 
Watkins, Maier, & Goehler, 1995). More specifically, reciprocal inhibitory feedback 
loops (see Figure 2) involving proinflammatory cytokines (e.g., IL-1, IL-6, and TNF- 
alpha) and hypothalamic-pituitary-adrenal (HPA) products (e.g., cortisol) are important
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for the homeostatic modulation of biological processes induced in response to infection 
and to physical or psychological stress.
Infection-initiated responses. When the body is invaded with a foreign molecule 
or pathogen, scavenger immune cells (e.g., macrophages) recognize, engulf, and destroy 
the invader. This process signals the release of proinflammatory cytokines that act to 
en h an ce  the immune response by recruiting and activating other immune mechanisms 
(i.e., cell-mediated and humoral immunity involving T and B lymphocytes). Along with 
enhancing immune activity, cytokines signal the brain to produce physiological changes 
that slow down certain activities in order to redirect energy and resources toward other 
processes necessary for combating infection and promoting recovery (Janeway & 
Travers, 1997; Maier, Watkins, & Fleshner, 1994). The resultant changes are often 
collectively referred to as “illness or sickness behaviour:” fever, malaise, fatigue, 
depressed mood, decreased appetite, accelerated weight loss, increased need for sleep, 
reduced sex drive, increased sensitivity to pain, and reduced cognitive efficiency (Maier 
& Watkins, 1998).
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Figure 2. Complex interconnections between the central nervous system, hypothalamic- 
pituitary axis, and immune system forming a reciprocal inhibitory feedback mechanism 
that mediates various physiological and behavioural responses.
Note. Solid line = stimulatory effect, Dotted line = inhibitory effect
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As proinflammatory receptors tend to be concentrated within the same brain 
regions responsible for regulating HPA axis responses, immune activation leads to the 
cascade production of corticotropin-releasing factor (CRF), adrenocorticotropic hormone 
(ACTH), and glucocorticoids. Stimulation of the HPA axis provides a negative feedback 
regulatory mechanism to suppress immune responses, preventing cytotoxic immune 
reactions from getting out of control and causing excessive tissue damage (Decker, 
Schondorf, Bidlingmaier, Himer, & von Ruecker, 1996; Elenkov, Papanicolaon, Wilder, 
& Chrousos, 1996; Marshall et al., 1998). Elevations of various HPA molecules have 
been associated with modulation of several components of immune responses, including 
suppression of T-cells, macrophages, and NK cells’ function (e.g., Homo-Delarche et al., 
1991; Nair, Saravolatz, & Schwartz, 1995; Pawlikowski, Zelazowski, Dohler, & Stepien, 
1988) and down-regulating gene transcription and mRNA translation of cytokines (e.g., 
Bateman, Singh, Krai, & Solomon, 1989; Cupps & Fauci, 1982; Joyce, Steer, & 
Abraham, 1997; Munck, Guyre, & Holbrook, 1984; Vacca et al., 1992).
Stress-initiated responses. Alternatively, the HPA axis may be initially stimulated 
in the presence of acute physical or psychological stressors. Activation of brain regions 
signals the increased production of HPA molecules. The release of glucocorticoids into 
the bloodstream triggers mobilization of energy sources necessary to respond to the 
stress, including elevating glucose availability, increasing cardiovascular tone, and 
enhancing cognition, while limiting other activities such as growth, reproduction, 
digestion, and immune responses (Alderson & Novak, 2002; Brooke & Sapolsky, 2000). 
Following the acute onset of a stressful situation, the neuroendocrine system can become 
sensitized in order to facilitate any subsequent responses to stressors. However,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
14
prolonged exaggerated stress may result in the opposite effect, habituation and decreased 
reactivity o f the HPA axis (Alderson & Novak, 2002; McEwen & Stellar, 1993). Chronic 
dysregulation of the HPA system may result in reduced appetite, weight loss, lethargy, 
weakness, gastrointestinal difficulties, and cognitive impairment (Baxter & Tyrell, 1994).
Recent evidence suggests that cytokines and HPA axis hormones may also 
influence neurotransmitter systems within the brain (for review see Muller & Ackenheil, 
1998; Wichers & Maes, 2002). In acute stress situations, both the HPA axis and 
noradrenergic (NE) systems are initially activated. Subsequent activation of the 
serotonergic (5-HT) system inhibits these circuits and reduces the stress response. 
However, prolonged stress may contribute to dysregulation of the HPA axis and 
imbalanced interactions between NE (hyperactive) and 5-HT (hypoactive) (Ressler & 
Nemeroff, 2000). Proinflammatory cytokines can further influence neurotransmission by 
altering the degradation of tryptophan, a precursor to 5-HT. Overstimulation of 
indoleamine 2,3-dioxygenase (IDO), the enzyme responsible for breaking down 
tryptophan, by cytokines leads to depletion of plasma concentrations of tryptophan and 
ultimately a reduction in the synthesis of 5-HT in the brain (Heyes et al., 1992). The 
disturbances in neurotransmitters accompanying cytokine/HPA activation may further 
increase an individual’s susceptibility to develop depression and declines in cognitive 
functioning (Widner, Laich, Spemer-Unterweger, Ledochowski, & Fuchs, 2002).
In summary, the intricate connections between cytokine and endocrine 
messengers, perhaps mediated through alterations in neurotransmitter systems, forms a 
reciprocal negative feedback mechanism that initiates and controls a wide variety of 
physiological and behavioural responses. Although transient elevations in cytokines and
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hormones are adaptive in managing acute infection or responding to physical and 
psychological stressors, chronic elevations or deficiencies due to significant disruptions 
to immune, neural, and/or endocrine activities in certain disease states may disrupt the 
structural and functional integrity of the other systems and consequently lead to 
prolongation or exacerbation of certain “illness behaviours” (Brooke & Sapolsky, 2000; 
McEwen, 2000).
Investigations o f biological correlates o f fatigue, cognitive symptoms, and depression in 
healthy controls, medical illnesses, and mood disorders
The pattern of physiological, behavioural, and cognitive alterations associated 
with dysregulation of proinflammatory cytokine/HP A/neurotransmitter processes 
resembles some of the symptoms accompanying various immune-mediated illnesses, 
including those commonly seen in HTV/AIDS. Although cytokine and immune alterations 
have been implicated in the manifestations of many medical conditions and major 
depression (Malek-Ahmadi, 1996), their relation to the pathogenesis underlying specific 
symptoms remains to be elucidated. Some preliminary studies have begun to explore the 
links between systemic biological indicators, fatigue (see Table 1), and cognitive status 
(see Table 2) in healthy individuals and in patients with various medical conditions. 
Moreover, new findings support the hypothesis that some individuals suffering from 
major depression may exhibit alterations in their inflammatory responses (see Table 3) 
and successful treatment with antidepressants may exert immunoregulatory effects (see 
Table 4).
Results from the following studies suggest that systemic immune and endocrine 
markers may provide a useful means to monitor biological changes and to investigate 
their association with overall disease processes as well as with specific mood, somatic,
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and cognitive symptoms. While diverse methodological approaches and sample . 
characteristics limits the direct comparison of research findings, studies measuring group 
differences (e.g., mean levels of biological markers in cancer patients with and without 
depressive symptoms), more so than associations (e.g., correlations between biological 
markers and the severity of depressive symptoms in cancer patients), have demonstrated 
links between elevated clinical symptoms and some biological indicators. In particular, 
fatigue and depressive symptoms were most consistently associated with elevated serum 
levels of IL-6, TNF-alpha, and neopterin. Although only a few studies have examined the 
association between cytokine profiles and cognitive symptoms, preliminary findings 
suggest that IL-6 (and TNF-alpha to a lesser extent) may be useful markers in this regard. 
Many studies have also documented associations between serum cortisol levels 
(especially under experimental manipulations), depression, and impaired cognitive 
functioning.
Healthy adults with immune/HPA activation elicited under experimental 
conditions. Recent studies from groups in Germany have explored the links between 
systemic biological indicators (various proinflammatory cytokines and HPA products) 
and alterations in cognitive, somatic, and mood symptoms in healthy controls. Spath- 
Schwalbe et al. (1998) examined the effects of systemically administering low doses of 
IL-6 on mood, sleep, and cognitive symptoms in 16 healthy men. Prolonged increases in 
plasma concentrations of ACTH and cortisol and a mild rise in body temperature 
accompanied the induced elevations in IL-6. In comparison with a placebo group, the 
participants receiving IL-6 subjectively reported more fatigue and trouble with 
concentrating. Sleep patterns were significantly altered with decreased rapid eye
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movements apparent throughout the night. In sleep-deprived (otherwise healthy) males, 
Vgotzas (1999) also noted that elevated levels of IL-6 corresponded with measures of 
daytime fatigue.
Reichenberg et al. (2001) investigated the cognitive and behavioural 
consequences of inducing immune activation in a sample of twenty healthy male 
volunteers. Elevations in plasma levels of TNF-alpha, TNF-alpha receptors, IL-6, and 
cortisol levels were reported following the injection of an endotoxin {Salmonella abortus 
equi). Despite limited changes in participants’ subjective rating of physical illness 
symptoms, elevations in TNF-alpha and cortisol plasma concentrations were 
accompanied by transient increases in anxiety and depressed mood, as well as decreased 
performance on measures of verbal and nonverbal memory.
Impaired learning and memory (particularly paragraph and word list recall tasks) 
have also been consistently documented in healthy individuals exposed to experimental 
conditions designed to elevate their cortisol levels (e.g., Newcomer, Craft, Hershey, 
Askins, & Bardgett, 1994; Vedhara, Hyde, Gilchrist, Tytherleight, & Plummer, 2000; 
Wolf, Schommer, Hellhammer, McEwen, & Kirschbaum, 2001). For example, 
Kirschbaum, Wolf, May, Wippich, and Hellhammer (1996) examined memory 
performance in conjunction with changes in cortisol levels in two separate samples of 
healthy individuals. In their first experiment, 13 participants were subjected to a 
psychological stressor that involved delivering a speech and performing mental math 
activities in front of an audience. Participants with higher cortisol responses to the 
stressor performed worse on a word list recall task. In their second experiment, 40 
participants were orally given either 10 mg cortisol or placebo pills, and then tested about
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an hour later on explicit verbal learning (i.e., eued-recall), implicit verbal learning (i.e., 
primed word stem completion), and spatial memory tasks (i.e., spatial locations of objects 
or directions along a path). As compared to those in the placebo group, the participants 
who were administered the cortisol recalled fewer words during cued-recall and made 
more errors on the spatial tasks, though no difference in performance was noted across 
groups for the stem-completion exercise.
Brief single dose treatment may not completely reflect the elevated cortisol levels 
typically associated with stressful conditions. Newcomer et al. (1999) examined the 
effects of prolonged durations of hypercorticolemia in healthy volunteers. Administration 
of cortisol supplements to mimic doses associated with physical and psychological stress 
over longer periods (4 days) in healthy adults also resulted in poorer recall on a verbal 
paragraph learning test.
Medical conditions. Elevated levels of proinflammatory cytokines and markers of 
immune activation (e.g., neopterin) have routinely been used to gauge overall disease 
progression in various immune-mediated diseases, such as systemic lupus erythematosus 
(SLE), cancer, Sjogren’s syndrome, arthritis, chronic fatigue syndrome, and multiple 
sclerosis (MS) (e.g., Andrys, Rrejsek, Slezak, Drahosova, & Kopecky, 1999; Altingdag, 
Sahin, Isimer, Akpek, & Kansu, 1999; Giovannoni et al., 1997; Maimone, Gregory, 
Amason, & Reder, 1991; Sorensen, 1999; Rentzos et al., 1996; Widner et al., 1999). 
More recently, studies have begun to explore possible relations between immune 
mediators and specific somatic, depressive, and cognitive symptoms in some of these 
immune-based medical conditions.
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Kurzrock (2001) reviewed possible behavioural implications of proinflammatory 
cytokines (e.g., anemia, weight loss, night sweats, and pain) that may contribute to 
cancer-related fatigue. Bower, Ganz, Aziz, and Fahey (2002) reported elevated serum 
levels of TNF receptors and neopterin, as well as lower serum levels of cortisol in breast 
cancer 5-year survivors with fatigue as compared with survivors without complaints of 
fatigue. Acute cancer patients with fatigue prior to commencing radiation treatment had 
higher IL-6 levels and immune cell counts than acute cancer patients without fatigue 
(Wratten et al., 2004). In contrast, some studies on radiation-induced fatigue in cancer 
patients have failed to find associations between levels of fatigue and changes (post­
treatment versus baseline) in proinflammatory cytokine levels with radiation (e.g., 
Ahlberg, Ekman, & Gaston-Johansson, 2004; Geinitz et al., 2001). Discrepant findings 
may, in part, reflect the diversity of cancer types, disease stages, treatment approaches, 
and measures.
Elevations in proinflammatory cytokines (TNF-alpha, IL-1, and IL-6) and 
occasionally cortisol levels have also been associated in some studies of fatigue in 
individuals with sleep apnea (Vgontzas et al., 2000), acute coronary disease recovering 
from surgery (Appels, 1999), multiple sclerosis (e.g., Flachenecker et al., 2004), and 
chronic fatigue syndrome (Buchwald et al., 1997; Cleare et al., 2004; Mullington, Jinze- 
Selch, & Pollmacher, 2001; Patarca, 2001).
Cytokine-induced behavioural changes also resemble some of the vegetative 
symptoms associated with depression, including anorexia, weight loss, psychomotor 
retardation, sleep disturbances, and anergy (Maes, 1993). Mussel man et al. (2001) 
compared plasma concentrations of IL-6 and cortisol levels following dexamethasone
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suppression in a group of cancer patients diagnosed with or without comorbid depression. 
The cancer patients with major depression (n = 8) had markedly higher plasma IL-6 
levels than cancer patients without major depression (n = 13) and healthy controls (n = 
10). Scores on the depression measure (Hamilton Depression Rating Scale) were 
positively correlated with cortisol levels, though no association was evident for IL-6 
plasma levels. Similarly, elevations in plasma IL-6 concentrations have been described in 
depressed patients with rheumatoid arthritis (RA) as compared with non-depressed 
controls without RA or RA patients without depression (Zautra et al., 2004).
Kahl, Kruse, Fahler, Weiss, and Reickmann (2002) examined the association 
between mRNA TNF-alpha levels, depressive symptoms, and disability status in a group 
of recently diagnosed patients with MS (n = 16) and demographically matched healthy 
controls. MS patients demonstrated higher TNF-alpha mRNA expression and depressive 
symptoms than controls. Depressive symptoms, but not disability status, was positively 
correlated with TNF-alpha expression both at baseline and 3 to 6 months later.
Although increased levels of proinflammatory cytokines have commonly been 
reported in multiple sclerosis, fibromyalgia and chronic hepatitis C infection, some 
studies have failed to find consistent associations between symptom measures of fatigue 
or depression and systemic markers of inflammatory disease activity (e.g., Gershon, 
Margulies, Gorczynski, & Heathcote, 2000; Giovannoni, Thompson, Miller, & 
Thompson, 2001; Gur et al., 2002). However, the majority of these studies examined 
associations between symptom severity within a single patient group rather than the 
aforementioned studies that compare conditions with control groups.
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Adults with chronic glucocorticoid elevations or deficiencies often demonstrate 
cognitive impairments, in particular on certain types of learning and memory tasks. 
Difficulties on explicit memory tasks (e.g., word list or paragraph recall) have been 
observed in individuals with rheumatoid arthritis who were administered prolonged doses 
of exogenous glucocorticoids like prednisone (Keenan, Jacobson, Soleymani, & 
Newcomer, 1995; Keenan et al., 1996). Elevated cortisol levels in patients with 
depression were positively correlated with problems on tests of verbal memory (Sheline, 
Wang, Gado, Csemansky, & Vannier, 1996; van Londen et al., 1998). Higher cortisol 
levels in Alzheimer disease patients were associated with poorer performance on 
cognitive screening measures (Rasmuson et al., 2001; Umegaki et al., 2000; Weiner, 
Vobach, Olsson, Svetlik, & Risser, 1997). Moreover, individuals with Cushing’s disease 
often experience cognitive problems and reductions in plasma cortisol levels following 
treatment has led to some improvements in cognitive functioning, especially on verbal 
paired-associate learning and recall tasks (Mauri et al., 1993; Starkman et al., 1992).
Much less research is available on the specific cognitive changes mediated by 
cytokines. Kozora et al. (2001) examined the contribution of IL-6, cortisol, and 
dehydroepiandrosterone (DHEA) to cognitive impairments in 15 individuals with SLE 
and 15 individuals with RA. In comparison with 15 age-matched controls, SLE and RA 
patients performed significantly worse than controls on measures of attention, and SLE 
patients performed significantly worse than RA and controls on measures of list, 
paragraph, and figure recall. Cognitive impairments, especially in SLE group, were 
associated with abnormal levels of DHEA and IL-6 but not cortisol even after controlling 
for potentially confounding factors such as depression and corticosteroid treatment.
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Weaver et al. (2002) investigated the relation between plasma IL-6 and risk for 
cognitive decline in a sample of 779 elderly men and women. Higher baseline levels of 
IL-6 were marginally associated with poorer baseline cognitive functioning even after 
controlling for various demographic, social, and health variables. Individuals with higher 
baseline levels of IL-6 were also more likely to exhibit cognitive declines at follow-up 2 
Vz and 7 years later. In a similar prospective study enrolling 3031 older adults, Yaffe et 
al. (2003) reported associations between elevated baseline serum IL-6 and cognitive 
decline at 2-years follow-up. The authors suggested that serum markers of immune 
activation may provide a practical means to monitor and predict older individuals at-risk 
for cognitive decline. Recently, Mantovani et al. (2004) examined the significance of 
serum IL-6 elevations in older adults with cancer. While higher IL-6 was not directly 
associated with general measures of cognitive status, IL-6 levels did correlate with 
measures of functional activities of daily living.
Mood disorders. Evidence has recently emerged suggesting that major depression 
may be accompanied by moderate immune activation. Maes and colleagues (1993, 1995) 
reported an increase in the plasma concentration and in vitro production of IL-1 and IL-6 
in patients with Major Depressive Disorder (MDD) in comparison with non-depressed 
controls. They indicated that increased levels of proinflammatory cytokines correlated 
with severity of the depressive illness, elevated cortisol, and decreased tryptophan levels. 
The vast majority of studies reviewed similarly found elevations in plasma concentrations 
of proinflammatory cytokines (in particular IL-6) in individuals with MDD, dysthymia, 
and seasonal affective disorder (e.g., Leu, Shiah, Yatham, Cheu, & Lam, 2001; Penninx 
et al., 2003; Schlatter, Ortuno, & Cervera-Enguix, 2004; Sluzewska et al., 1996; Suarez,
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Ranga, Krishnan, & Lewis, 2003; Trzonkowski et al., 2004). Elevated indicators of cell- 
mediated immunity, including increased monocyte counts and production of neopterin, 
have also been observed in depressed individuals (e.g., Bonaccorso et al., 1998; Dunbar 
et al., 1992; Maes et al., 1994).
Selective serotonin reuptake inhibitors (SSRI) and tricyclic antidepressant (TCA) 
medications have shown immunosuppressant effects both in vivo and in vitro (for review 
see Maes, 2001). Animal models have demonstrated inhibitory influences of SSRIs on 
the production of acute phase proteins and proinflammatory cytokines (Song & Leonard, 
1994). An in vitro study conducted by Xia, DePierre, and Nassberger (1996) found that 
various SSRIs and TCAs inhibited proinflammatory cytokine release in samples of 
stimulated human blood monocytes. However, Kubera et al. (2004) noted that patients 
with treatment-resistant depression showed increased production of IL-6 in their blood 
cell samples when antidepressants were added. Prolonged treatment with SSRIs has lead 
to normalization of serum IL-6 levels in depressed patients relative to controls 
(Frommberger et al., 1997; Sluzewska et al., 1995). However, many studies have not 
observed corresponding changes in proinflammatory cytokine levels with short-term 
antidepressant treatment (e.g., Brambilla et al., 1998; Kubera et al., 2000; Mikova et al., 
2001). Study methodology, severity and chronicity o f the mood disturbance, durations of 
therapeutic doses, types of antidepressants, and individuals differences in response to 
antidepressant treatment may account for some of the discrepant findings. Interestingly, 
Lanquillon et al. (2000) reported that higher TNF-alpha production by blood 
mononuclear cells was reduced after a 6-week treatment with amitriptyline in treatment 
responders, but not in individuals unresponsive to the antidepressant treatment.

















Selected studies comparing the link between fatigue and biological markers
1st Author (year) Sample NTa Ncb Measure Lab markers0 Group0 re
Ahlberg (2004) Women with uterine cancer 
undergoing radiation therapy 
(baseline, 3 wks & after 
treatment)







Appels (1999) Acute coronary disease patients 
with fatigue cf. patients without
fatigue




Bower (2002) Breast cancer 5-year survivors 
with fatigue cf. patients without 
fatigue
20 20 RAND 36-item Health Survey: 
Energy/ Fatigue subscale
TNF-receptors (s) 






Buchwald (1997) Individuals with chronic fatigue 
cf. standard clinical range






Cannon (1999) Individuals diagnosed with 
chronic fatigue syndrome cf. 
controls
6 4 Self-report exertion after 15 
minutes exercise






Cleare (2004) Individuals with chronic fatigue 
syndrome without depression cf. 
controls




Flachenecker (2004) Multiple sclerosis patients with 
fatigue cf. patients without 
fatigue






Geinitz (2001) Breast cancer patients during the 
course o f radiation therapy 
(baseline & 2 months post)
41 41 Fatigue Assessment Questionnaire 








Gershon (2000) Adults diagnosed with Chronic 
Hepatitis C






















Giovannoni (2001) Multiple sclerosis patients 38 Fatigue Questionnaire Scale & 




Omdal (2002) Patients with systemic lupus 5 Fatigue Severity Scale IL-2 (s) ns
erythematosus IL-6 (s) ns
IL-10 (s) ns
TNF-alpha (s) ns
Patarca (1994) Patients with chronic fatigue 70 TNF-alpha (s) t
syndrome cf. standard clinical TNF-beta (s) t
ranges IL-1 (s) t
IL-2 (s) t
IL-2 receptor (s) t
Neopterin (s) t
Spath-Schwalbe Healthy men administered low- 16 16 Self-report fatigue & REM sleep IL-6 (s) t +
(1998) dose IL-6 cf. placebo ACTH (s) t +
Cortisol (s) t +
Vgontzas (1999) Healthy males in sleep 8 Amount and depth of sleep at baseline IL-6 (s) .
deprivation experiment Daytime sleepiness and fatigue +
Vgontzas (2000) Men with sleep apnea cf. 14 23 Sleep disturbance & daytime TNF-alpha (s) t
nonapneic matched controls sleepiness IL-6 (s) t
Wallace (2001) Patients with fibromyalgia with 56 56 Self-report fatigue IL-1 receptor (s) t
fatigue cf, controls IL-8 (s) t
IL-6 (stim) t
Wratten (2004) Acute cancer patients starting 21 28 Functional Assessment of Cancer IL-6 (s) f +
radiation therapy with fatigue cf. Therapy
patients without fatigue
Note, 8NT= sample size for treatment or condition group; t’Nc = sample size for control group, cIL=interleukin, TNF=tumor necrosis factor, IFN = interferon, 
ACTH = adrenocorticotropic hormone, CRP = C-reactive protein, s = serum levels, u = urinary levels, mRNA- levels of mRNA expression, stim = levels 
following stimulation ofPBMCs with mitogen (LPS/PHA), A = change in marker over time; d t  = elevated levels in condition versus control group, I  = lower 
levels in condition versus control group, ns = non-significant difference between condition and control;e + = significant positive correlation (i.e., increased 




















Selected studies comparing the link between cognitive function and biological markers
1st Author (year) Sample N / N c b Measures Lab markers0 Groupd Assoc®
Errico (2002) Alcoholic males during 
early withdrawal
18 1. Verbal Memory (Story recall)
2. Cognitive Flexibility (Wisconsin Card 
Sorting Test)
f  Cortisol (s) 1. - 
2. -
Keenan (1995) Patients with rheumatoid 
arthritis on prolonged 
prednisone treatment cf. 
patients with no treatment
25 25 1. Verbal Memory (Paragraph recall)
2. Non-declarative Memory (Word-stem 
priming)





exposed to psychosocial 
stressor (Trier Social Stress 
Test)
13 Verbal Memory (Recall of 26-item word 
list)




administered cortisol cf. 
placebo
20 20 1. Verbal Declarative Memory (Cued 
recall word list)
2. Spatial Memory (park pathway & bam 
location)
3. Procedural Memory (Word-stem 
completion task)
T Cortisol (s) 1. 4
2. 4-
3. ns
Kozora (2001) Patients with Systemic 
Lupus Erythematosus cf. 
matched-controls
15 15 Learning Index (Immediate Story Recall, 
Immediate Figure Recall, & Word List 
Learning) and Attention Index (Digit 
Vigilance Test & Paced Auditory Serial 
Addition Test)
i  IL-6 (s)




Lupien (1999) Healthy men with varying 
doses of hydrocortisone cf. 
placebo
30 10 1. Working Memory (Item-Recognition 
Task)
2. Verbal Declarative Memory (Recall of 
Word Pairs)
t  Cortisol (s) 1. i
2. ns
Mantovani (2004) Older adults with cancer 84 1. Cognitive Status
2. Functional Activities of Daily Living
f  IL-6 (s) ns
Mauri (1993) Cushing’s syndrome 
patients cf. matched controls
25 25 Verbal Memory (Paragraph recall & 


















Newcomer (1994) Healthy adults administered 
dexamethasone cf. placebo
10 9 Verbal Memory (Immediate & Delayed 
Paragraph Recall)
i  Cortisol (o, 
dex supp)
4
Newcomer (1999) Healthy participants 
administered low and high 
doses of cortisol for 4 days 
cf. placebo group
31 20 Verbal Memory (Immediate and Delayed 
Paragraph Recall)
t  Cortisol (s) 4
Rasmuson (2001) Women with Alzheimer 
disease c f  young & older 
healthy women
10 14 Clinical Dementia Rating Scale t  Cortisol 
metabolites (u)
I
Reichenberg (2001) Healthy males injected with 
an endotoxin cf. placebo
20 20 Verbal Memory (Story Recall & List 
Learning) and Visual Memory (Figure 
Recall)
t  TNF-alpha (s) 
t  Cortisol (s) 
f  IL-6 (s)
ns
Sheline (1996) Depressed patients cf. 
matched controls





Healthy men administered 
low-dose IL-6 cf. placebo
16 16 Self-report difficulties with concentration t  IL-6 (s) 
t  ACTH (s) 
t  Cortisol (s)
+
Starkman (1992) Cushing’s syndrome 
patients
12 Verbal Memory (Paragraph recall & 
Paired Associates Learning tasks)
t  Cortisol (s) »
Umegaki (2000) Patients with Alzheimer 
disease and vascular 
dementia cf. control elderly
94 21 Mini Mental Status Examination TCortisol (s)
Van Londen (1998) Depressed patients cf. non­
depressed controls
15 15 Verbal Memory (Paragraph recall & List 
learning)
t  Cortisol (s) 4
Vedhara (2000) Students during exam 
periods cf. students during 
non-exam periods
60 60 1. Attention (Test of Everyday Attention)
2. Verbal Memory (Primacy Effect for 
20-item Word List)
3. Verbal Memory (Immediate Recall)
4- Cortisol (o) 1. +
2. + 
3 .-
Weaver (2002) Older adults 779 Modified Mini Mental Status 
Examination (Cognitive status at 2Vz and 
7 yrs follow-up)
T IL-6 (s) at 
baseline
Weiner (1997) Patients with Alzheimer
disease
9 Modified Alzheimer Disease Assessment 
Scale-Cognitive (Change score from 





















Widner (2000) Patients with Alzheimer 
disease cf. similar aged 
controls
21 20 Mini Mental Status Examination I  Tryptophan (s) +
Wolf (2001) Healthy participants 
exposed to psychosocial 
stressor (Trier Social Stress 
Test) cf. controls
22 36 Verbal Learning (Immediate Recall of 
Word List)
t  Cortisol (o): 
men




Wolkowitz (1990) Depressed patients 21 Verbal Memory (Word list recognition 
task)
tCortisol (s, dex 
supp)
Yaffe (2003) Older adults 3031 Modified Mini Mental Status 
Examination
(Cognitive status at 2-year follow-up)
At Baseline: 
t  IL-6 (s) 
f  CRP (s) 
t  TNF-alpha (s) ns
Note. aNT= sample size for treatment or condition group; “TSfc ~ sample size for control group; cIL=interleukin, TNF=tumor necrosis factor, ACTH ~
adrenocorticotropic hormone, DHEA = dehydroepiandrosterone, CRP = C-reactive protein, s = serum levels, o = saliva levels, dex sup= serum levels under 
conditions of dexamethasone suppression, t  = elevated levels, I  = low levels;* t  = poorer performance on test in condition versus control group, ns = no 
difference between condition and control performance;f + = positive correlation between performance and serum levels, - = negative correlation between 




















Selected studies comparing the link between depression and biological markers
1st Author (year) Sample3 NTb Ncc Diagnosisd Measure Lab markers® Group r8
Anisman (3999) Patients with MDD or 














Appels (2000) Patients with coronary artery 
disease with depressive 
symptoms/exhaustion cf. 









Bonaccorso (1998) Patients with MDD c f normal 
controls
10 17 DSM-IIIR Neopterin (u) t
Brambilla (1998) Elderly women with MDD 
(inpatients) c f  matched 
controls











Carpenter (2004) Patients with MDD cf. 
matched controls
18 26 DSM-IV IL-6 (csf) ns
Frommberger (1997) Patients with MDD cf. healthy 
controls
(*acute MDD vs. **MDD in 
remission)
12 12 DSM-IIIR Montgomery Asberg 
Depression Rating
IL-6 (s) f  (*)
ns (**)
Glaser (2003) Older adults 119 Beck Depression
Inventory
IL-6 (s) +
Gur (2002) Patients with Fibromyalgia 
and depressive symptoms cf. 
healthy controls
81 32 Hamilton Depression 
Rating Scale
IL-1 (s)







Gur (2004) Patients with fibromyalgia 
(FM) and chronic fatigue 
syndrome cf. healthy controls




















Kahl (2002) Multiple sclerosis patients cf. 
healthy controls













Leu (2001) Patients with Seasonal 15 15 IL-6 (s) f
Affective Disorder cf, IL-6 receptor (s) OS
matched normal controls IL-2 receptor (s) ns
Maes (1995) Patients with MDD (acute and 77 38 DSM-IIIR Hamilton Depression IL-6 (s) t
chronic remission) cf. healthy Rating Scale IL-6 receptor (s) t
controls IL-2 receptor (s) t
Maes (1997) Patients with MDD (including 35 15 DSM-IIIR Hamilton Depression IL-1 receptor (s) t ns
treatment-resistant depression) Rating Scale Il-6(s) t ns
cf. non-depressed controls
Mikova(2001) Patients with MDD cf. 28 15 DSM-IV IL-6 (s) t
controls IL-8 (s) ns
TNF-alpha (s) t
IL-2 receptors (s) ns
Musselman (2001) Cancer patients with comorbid 8 13 DSM-IIIR Hamilton Depression IL-6 (s) t ns
MDD cf. cancer patients Rating Scale Cortisol (s, dex sup) t 4*
without depression
Natelson (1999) Patients with chronic fatigue 30 87 DSM-IIIR Centers for IL-1 (mRNA) 4
syndrome and comorbid MDD Epidemiological IFN-gamma (mRNA) ns






Penninx (2003) Elderly adults with depressive 145 2879 Centers for IL-6 (s) t
symptoms cf. normal controls Epidemiological TNF-alpha (s) t
Study-Depression CRP (s) t
Reichenberg (2001) Healthy males injected with an 20 Depression TNF-alpha (s) 4~
endotoxin Adjectives Check Cortisol (s) +
















Schlatter (2004) Patients with MDD or 
dysthymia cf. healthy controls











Sluzewska(1996) Inpatients with MDD cf. non­
depressed controls
49 15 DSM-IIIR Hamilton Depression 
Rating Scale
IL-6 (s)











Starkman (1992) Patients with Cushing’s 
disease
11 Hamilton Depression 
Rating Scale
ACTH (s, dex sup) +








Trzonkowski (2004) Elderly with MDD cf. non­
depressed controls








Zautra (1994) Individuals with rheumatoid 
arthritis
33 Beck Depression 
Inventory
Cortisol (s) 
Prolactin (s) _ .
ns
4-
Zautra (2004) Rheumatoid arthritis (RA) 
patients with comorbid MDD 
cf. RA patients without 
depression and healthy 
controls
45 106 DSM-IV IL-6 (s)
Note.a MDD=major depressive disorder; "Nr = sample size for treatment or condition group; CNC = sample size for control group,
dD SM  = Diagnostic and Statistical Manual of Mental Disorders; eIL=interleukin, TNF=tumor necrosis factor, ACTH = adrenocorticotropic hormone, CRP = C- 
reactive protein, IFN = interferon, NE = norepinephrine, s = serum levels, csf= cerebral spinal fluid levels, u = urinary levels, dex sup= serum levels under conditions of 
dexamethasone suppression, mRNA= levels of mRNA expression, stim = levels following stimulation ofPBMCs with mitogen (LPS/PHA); f t  = elevated levels in 
condition versus control group, I  ~ lower levels in condition versus control group, ns = non-significant difference between condition and control groups;g + = 
significant positive correlation (i.e., increased severity of depression associated with elevated level of marker), - = significant negative correlation (i.e., increased 


















Selected studies investigating the effects o f antidepressants on biological indicators
1st Author (year) Sample3 NTb Ncc Treatment Duration Lab markers Group® Change1
Brambilla (1998) Elderly women with MDD 10 20 Phosphatidylserine 30 days IL-1 (s) ns ns
(inpatients) cf. matched controls IL-6 (s) ns ns
TNF-alpha (s) ns ns
Kubera (2000) Patients with MDD cf. non­ 9 10 Unspecified antidepressants 6 weeks IL-1 receptor (s) t ns
depressed controls IL-6 (s) t ns
IL-10 (s) t ns
Kubera (2004) Treatment-resistant depressed 7 19 Imipramne, venlafaxine, L-5-HT, IL-6 (stim) t
patients cf. controls or fluoxetine TNF-alpha (stim) ns
Lanquillon (2000) Inpatients with MDD cf. controls 24 Amitryptiline 6 weeks IL-6 (s) T(*) ns
(*non-responders **responders) TNF-alpha (s) t  (both) i(**)
Maes (1995) Patients with MDD (acute and 77 38 Mixed sample (fluoxetine, 81.2+/-38.3 IL-6 (s) t ns
chronic remission) cf. healthy nortiptyline, amitryptiline, or days IL-6 receptor (s) t ns
controls imipramine) IL-2 receptor (s) f ns
Maes (1997) Patients with MDD (including 35 15 Trazodone alone, Trazadone with 5 weeks IL-1 receptor (s) t ns
treatment-resistant depression) cf. pindolol or Trazadone with IL-6(s) f ns
non-depressed controls fluoxetine IL-6 receptor (s) t I
Maes (1999) Normal healthy adults 9 Clomipramine, sertraline, or IFN-gamma (stim) 4
trazadone IL-10 (stim) t
Mikova (2001) Patients with MDD cf. controls 14 15 Mixed sample (clomipramine, 6 weeks IL-6 (s) f ns
paroxetine, mianserin, or IL-8 (s) ns ns
amitriptyline) TNF-alpha (s) t ns
IL-2 receptors (s) ns ns
Weizman (1994) Patients with MDD cf, matched 10 10 Clomipramine 4 weeks IL-1 (stim) t
healthy controls IL-2 (stim) t
IL-3 (stim) t
X iaeta l. (1996) Normal healthy adults 4 Clomipramine, imipramine or IL-2 (stim) 4
citalopram IFN-gamma (stim) 4
TNF-alpha (stim) 4
IL-6 (stim)
... . d r r  : _i.:_ t
4
Note. MJJU=major depressive disorder; jnt = sample size ior treatment or condition group; rsc -  sampie size tor control group, uu-uucucwuu, r i>r—tumoi 
factor, IFN - interferon, s = serum levels, stim — levels following stimulation of PBMCs with mitogen (LPS/PHA);6 T = elevated levels in condition versus control 
group, 4 * lower levels in condition versus control group, ns = non-significant difference between condition and control group;f 4 = reduced levels over time with 
treatment, ns *= no significant changes in levels over time with treatment N3
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Potential neural correlates of “illness behaviour”
Given the higher density of proinflammatory cytokine and hormonal receptors 
located within the hypothalamus, hippocampus, basal ganglia, and prefrontal cortex 
connections, functions of these brain regions may be more susceptible to cytokine/HP A- 
induced activity. For brevity and readability the hypothesized functions of these brain 
structures are reviewed, though it is recognized that these structures do not function in 
isolation but rather operate as part of comprehensive pathways within the brain.
The multiple nuclei within the hypothalamus form intricate connections with 
diverse regions of the brain, including the brain stem, anterior thalamus, limbic cortex, 
hippocampus, and pituitary gland. Stimulation and lesion studies have shown that the 
hypothalamus is pivotal for the integrated control and maintenance of many different 
physiological activities, such as regulation of arterial pressure and heart rate, body 
temperature, sleep-wakefulness cycles, water conservation, hunger sensation, sexual 
drive, pain perception, and emotional control (Guyton, 1991). The hypothalamus co­
ordinates bodily functions in a rhythmic fashion (daily and seasonal cycles) as well as 
spontaneously in response to internal and external factors (Overeem et al., 2002).
The medial temporal lobe system is comprised of the hippocampus and adjacent 
cortical regions. Bidirectional projections exist between the hippocampus and entorhinal 
cortex. The entorhinal cortex forms reciprocal projections with parahippocampal and 
perirhinal cortices, as well as sends and receives information from orbitofrontal, 
cingulate, superior temporal gyrus, and insular cortices. The parahippocampal and 
perirhinal cortices have more widespread reciprocal connections with unimodal and 
polymodal association areas in frontal, temporal, and parietal lobes (Squire, 1992; Squire,
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Stark, & Clark, 2004). The integrity of the hippocampus and related structures has been 
linked to learning and memory. Convergent support comes from numerous lesion and 
imaging studies in rats, nonhuman primates, and humans (for detailed reviews see 
Eichenbaum, 1999; Lepage, Ghaffar, Nyberg, & Tulving, 2000; Squire, 1992; Squire, 
Knowlton, & Musen, 1993; Squire et al., 2004; Tulving & Markowitsch, 1998). In 
particular, declarative memory (also referred to as explicit, relational, contextual, or 
configurational memory) that involves the formation of relationships, transfer of newly 
acquired information to long-term storage, and recalling facts or events over short periods 
of time may be mediated by the medial temporal lobe system. The role of the 
hippocampal structures in learning and memory storage is thought to be temporary, such 
that memory gradually reorganizes so that permanent storage occurs in the neocortex 
(Squire, 1992; Squire et al., 2004). Following consolidation and more permanent storage 
of new information, retrieval of this information is thought to involve extra-hippocampal 
structures including the frontal cortex (Squire et al., 1993).
The ffontal-subcortical circuitry are highly complex and mediate a wide range of 
behaviours and motor activity. A series of five parallel circuits linking specific regions of 
the frontal cortex to the striatum, globus pallidus, and thalamus have been described (e.g., 
Alexander, DeLong, & Strick, 1987; Cummings, 1993; Tekin & Cummings, 2002). The 
motor circuit, originating in the supplementary motor area, premotor cortex, and motor 
cortex, is responsible for initiating and sequencing multiple successive and parallel 
muscle movements to achieve desired goals. The oculomotor circuit originates from the 
frontal eye field and posterior parietal cortex, and mediates the complexity o f eye 
movements. The dorsolateral prefrontal circuit is thought to be involved in cognitive
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tasks, such as planning, organization, regulating behaviours, shifting sets, and solving 
novel problems. Personality changes, behavioural disinhibition, and emotional lability 
may result from disruption of the lateral orbitofrontal circuit. The anterior cingulate 
circuit is thought to be important for motivation, such that lesions in this pathway result 
in apathy, indifference, and lack of motor and verbal initiation (for detailed review see 
Tekin & Cummings, 2002).
The neuropathology of HIV: At system, cellular, and molecular levels
Brain regions. Neuroradiology and pathology studies provide support for the 
potential disruption of both medial temporal and frontal-subcortical brain systems in 
HIV. Post-mortem analyses of individuals with AIDS often reveal cerebral atrophy with 
sulci widening and ventricular dilation (e.g., Poutiainen et al., 1993; Vago, Trabattoni, 
Lechi, Cristina, & Budka, 1990). Central white matter lesions and loss of specific 
subpopulations of neurons found within the basal ganglia, hippocampus, and frontal- 
temporal cortex are frequently observed (e.g., Bell, 1998; Gendelman et al., 1994; Wiley 
et al., 1991). For example, Reyes, Mohar, Mallory, Miller, and Masliah (1994) described 
neuronal atrophy and astrogliosis of the hippocampal formation, basal ganglia, and 
frontal cortex in 11 out of 19 autopsies of individuals with AIDS. High HIV viral DNA 
loads were also found in the medial temporal lobe region during post-mortem analyses of 
eight patients diagnosed with AIDS-related dementia (Fijumura et al., 1997). Petito, 
Roberts, Cantando, Rabinstein, and Duncan (2001) recently described neuronal loss, 
increased astrocyte gliosis, and the presence of high levels of cytokine co-receptors in 
hippocampal regions based on autopsies of 22 adults with AIDS.
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Similarly, structural imaging studies have documented diffuse cerebral atrophy, 
widening cortical sulci, enlarged ventricles, and periventricular white matter 
abnormalities in some individuals with HIY infection and AIDS (Elovaara et al., 1990; 
Raininko et al., 1992). Oberfield et al. (1994) noted the presence of hippocampal atrophy 
on 8 out of 15 CT scans of children with HIV infection. Decreased volume of the basal 
ganglia has also been observed and correlated with increased cognitive impairments (e.g., 
Aylward et al., 1993; Aylward et al., 1995; Hestad et al., 1993). Harrison et al. (1998) 
reported that the presence of white matter abnormalities on MRI scans was associated 
with poor overall neuropsychological performance and more specifically, declines on 
tests of executive functioning, psychomotor speed, and nonverbal memory.
Moreover, abnormal regional blood flow in temporal and frontal regions has been 
documented in patients with HIV infection relative to controls using both functional 
magnetic resonance imaging and positron emission tomography imaging scans (e.g., 
Chang, Ernst, Leonido-Yee, & Speck, 2000; van Gorp et al., 1992; Wiseman et al., 
1999). More marked abnormalities have been correlated with more advanced disease 
stage, lower CD4 T cell counts, higher viral loads, and increased cognitive impairments 
(e.g., Chang, Ernst, Leonido-Yee, & Speck, 2000; Chang et al., 2002; Hall, Whaley, 
Robertson, & Hamby, 1996).
Biological mechanisms. Progressive impairments in immune and CNS 
functioning in individuals with HIV are thought to result from both direct and indirect 
destruction of cells during the viral replication process (Gorman & Kertzner, 1990). The 
HIV virus has a predilection for cells with CD4 receptors (i.e., CD4 T lymphocytes, 
macrophages, and microglial cells). Macrophages are thought to be responsible for
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transporting HIV across the blood brain barrier and have been shown to enter the CNS 
within days to weeks of infection (e.g., Davis et al., 1992; Resnick, Berger, Shapshak & 
Tourtellotte, 1988). However, HIV does not seem to directly infect neurons or 
oligodendrocytes but instead reservoirs of virus are stored within brain macrophages, 
microglia, and multinucleated giant cells (e.g., Gendelman et al., 1994; Minagar et al., 
2002; Orenstein, 2001). Chronic low-grade activation of macrophages and microglia by 
HIV results in the release of a cascade of neurotoxic viral (e.g., protein gpl20) and/or 
cellular factors (e.g., proinflammatory cytokines, nitric oxide, oxygen radicals, 
prostaglandins, or leukotrienes) that can cause secondary damage to surrounding tissue 
(e.g., Brenneman, McCune, Mervis, & Hill, 1994; Gendelman et al., 1994; Minagar et al., 
2002).
Excess production of proinflammatory cytokines (most notably TNF-alpha) may 
have multiple adverse effects on their own: (1) stimulate microglia and astrocytes to 
produce additional neurotoxins such as arachidonic metabolites, quinolinic acid, and 
nitric oxide (Genis et al., 1992; Wesselingh et al., 1994; Pemberton, Kerr, Smythe, & 
Brew, 1997); (2) inhibit astrocytes from buffering extracellular glutamate which is also 
neurotoxic in excess amounts (Fine et al., 1996); (3) enhance HIV infection of host cells 
and viral replication processes (Alfano & Poli, 2001; Merrill & Chen, 1991; Vyakamam, 
McKeating, Meager, & Beverley, 1990); and (4) stimulate production of adhesion 
molecules and chemokines (MCP-1) that alter permeability of the blood brain barrier to 
immune cells (Fiala et al., 1997; Nottet et al., 1996).
The HIV virus may stimulate the HP A axis directly via the production of peptide 
sequences similar to pituitary regulatory hormones (e.g., ACTH) or indirectly by
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cytokines enhancing CRF secretion (Corley, 1995; Sapolsky, Rivier, Yamamoto, Plosky, 
Vale, 1987; Smith & Blalock, 1982; Woloski et al., 1985). Elevated cortisol levels and 
HPA axis imbalances, regardless of their aetiology, may hasten the progression of HIV 
infection by suppressing cell-mediated immune functioning and the production of Type 1 
cytokines (Clerici et al., 1997b; Corley, 1995; Rook, Onyebujon, & Stanford, 1993; 
Sapse, 1997). Interestingly, glucocorticoids may also further exacerbate the neurotoxic 
effects of gpl20. A synergistic increase in neuronal death was apparent in cultures of 
hippocampal, cortical, and striatal tissues from rats when both gpl20 and corticosterone 
(similar to cortisol in humans) were present (Brooke, Chan, Howard, & Sapolsky, 1997; 
Iyer, Brooke, & Sapolsky, 1998). Brooke and Sapolsky (2000) hypothesized that both 
gpl20 and glucocorticoids contributed to neuronal death by altering different aspects of 
cellular metabolism, and together accelerating the depletion of energy sources.
Although the exact mechanism by which HIV damages neurons is still unknown, 
these findings suggest that damage to brain systems may stem from death of neurons, 
disruption of neuronal functioning, and/or modification of neurotransmitter systems 
(Adle-Biassette et al., 1999; Bell, 1998; Everall et al., 1999) indirectly mediated through 
factors released from proximal virus-infected macrophages and microglia (Gendelman et 
al., 1994; Minagar et al., 2002). Neuronal destruction may be further amplified by the 
interaction and perpetuation of immune and endocrine molecules via positive feedback 
loops. Central white matter and deep grey matter are often characterized by infiltration of 
macrophages containing HIV virus, astrogliosis, and the development of microglial 
nodules and multinuclear giant cells (i.e., fused macrophages and/or glial cells often 
containing copious amounts of virus and surrounded by ineffective T cells) (Gendelman
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et al., 1994). The presence of miiltinttclear giant cells has been correlated with the degree 
of dementia (McArthur et al., 1999). As outlined above, the disruption of certain brain 
systems (hypothalamic, medial temporal, and frontal-subcortical) may contribute to 
somatic, cognitive, and depressive symptoms in some individuals. Consequently, it may 
be useful to examine whether individual differences in immune and endocrine 
functioning is associated with the presence of these symptoms in HIV. The present study 
selected systemic indicators reflective of different aspects of this mechanism: (1) HIV 
replication and disease status (CD4 T cell counts and viral load); (2) macrophage 
activation and cytotoxicity (neopterin); (3) proinflammatory cytokines (IL-6 and TNF- 
alpha); and (4) cortisol. Previous research in HIV on each of these measures will be 
reviewed in turn.
I. CD4 T cells and Viral Load: Studies have extensively documented the 
development of clinical symptoms and AIDS conditions following rapid declines in CD4 
T cells (Detels et al., 1987; Fahey et al., 1990). Although decline in CD4 T cell counts 
has served as the hallmark for disease progression (Fahey et al., 1998; Pantaleo et al., 
1993; Staszewski, DeMasi, Hill, & Dawson, 1998), relatively weaker associations have 
been reported between CD4 T cell counts and cognitive impairments in HIV/AIDS 
(Bomstein et al., 1991; Dal Pan et al., 1998).
Increased levels of viral load in cerebrospinal fluid (CSF) and plasma have also 
been correlated with the rate of CD4 T cell decline, poorer prognosis, and increased 
clinical disease stages in HIV/AIDS (Hogervorst et al., 1995; Mellors et al., 1997). Some 
studies have also reported a link between elevations in viral load and cognitive 
impairment, especially for individuals diagnosed with AIDS dementia (Brew, Pemberton,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Cunningham, & Law, 1997; Buffet et al., 1991; Farzadegan et al., 1992; Kim et al., 2001; 
Royal, Seines, Concha, Nance-Sproson, & McArthur, 1994; Singer et al., 1994). 
However, other studies have not found an association between plasma viral load and 
cognitive decline in HIV infection (Dal Pan et al., 1998; Robertson et al., 1998). Ellis et 
al. (1997) suggested that higher CSF viral load may only reflect increased risk of 
cognitive impairments when significant corresponding declines in CD4 T cell counts are 
also evident. Childs et al. (1999) compared the predictive value of both plasma viral load 
and CD4 T cell counts as markers of dementia and sensory neuropathy in a sample of 
1604 men with HIV infection over a 10 year period. Individuals with high plasma viral 
loads had an 8.5 fold greater risk of developing dementia and 2.3 fold greater risk of 
developing sensory neuropathy. Similarly, lower CD4 T cell counts were associated with 
a 3.5 fold greater risk for dementia and 1.4 fold greater risk for sensory neuropathy.
II. Neopterin: Neopterin is a compound derived from guanosine triphosphate that 
is released from macrophages following activation. High concentrations of neopterin are 
associated with production of reactive oxygen species. Hence, neopterin can serve as a 
marker of the level of macrophage activation and an estimate of the extent of oxidative 
stress in the immune system (Hamerlinck, 1999; Murr, Widner, Wirleitner, & Fuchs, 
2002).
Neopterin is markedly elevated upon initial infection with HIV. Levels of 
neopterin tend to decline somewhat after seroconversion, though they remain elevated in 
more than 75% of individuals with HIV in asymptomatic stages and progressively 
increase with advancing disease stages (Baier-Bitterlich, Wachter & Fuchs, 1996; Fahey 
et al., 1990; Fuchs et a l, 1989). Metha et al. (1996) reported that CSF levels o f neopterin
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progressively increased with advanced disease stages based on a subsample o f 377 
participants from the San Diego HIV Neurobehavioural Research Center study. 
Decreases in serum neopterin levels have also been documented after initiation of 
HAART regimens (Amirayan-Chevillard et al., 2000; Stylianou, Aukrust, Bendtzen, 
Muller, & Froland, 2000; Zangerele et al., 2002).
Griffin et al. (1991) examined serum and CSF concentrations of neopterin in 121 
individuals with HIV infection and 62 HIV-negative controls. Levels of neopterin were 
higher in individuals with HIV infection than the controls, and especially elevated in 
HIV-positive individuals with neurological diseases, such as HIV associated meningitis, 
opportunistic infections, and inflammatory demyelinating polyneuropathologies. CSF and 
serum neopterin levels have also been correlated with measures of increased blood brain 
barrier permeability (albumin ratio) in HIV-infected individuals at different stages of 
disease (Andersson, Hagberg, Fuchs, Svennerholm, & Gisslen, 2001).
Ill: IL-6 and TNF-alpha: Peripheral proinflammatory cytokines are involved in 
the initiation of localized and systemic immune responses, such as activation of liver cells 
to synthesize proteins necessary for other immune responses or vasodilation of blood 
vessels to increase their permeability for proteins and immune cells at the infection site 
(Janeway & Travers, 1997). They also monitor and modulate biological processes within 
the periphery by both directly and indirectly communicating with the CNS (for review 
see Maier & Watkins, 1998). Proinflammatory cytokines directly produced in the brain 
are thought to have pivotal roles in protecting neurons and mediating inflammation. 
However, both prolonged elevations and deficient levels can be detrimental to CNS 
functioning (Wang et al., 2002).
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Plasma levels of proinflammatory cytokines (IL-1, IL-6, and TNF-alpha) are often 
elevated in HIV disease, especially among patients with opportunistic infections (Valdez 
& Lederman, 1997-1998). Peripheral blood mononuclear cells isolated from patients with 
HIV have been shown to spontaneously release high levels of IL-1, TNF-alpha and IL-6, 
and increased release was correlated with advanced stages of HIV-1 infection (Berman, 
Zaldivar, Imfled, Kenney, & Sandborg, 1994; Honda et al., 1990; Roux-Lombard, 
Modoux, Cruchaud, & Dayer, 1989; Wright, Jewett, Mitsuyasu, & Bonavida, 1988). 
Although an in vivo study conducted by da Silva, Singer, Fong, and Ottaway (1999) 
found no differences in TNF-alpha and IL-6 levels at baseline, greater increases in serum 
TNF-alpha and IL-6 levels were evident after experimental challenge with 
lipopolysaccharide in individuals with HIV infection (n = 29) than in control subjects (n 
= 15).
Higher TNF-alpha and soluble TNF receptor concentrations in plasma were 
associated with increased disease progression, lower CD4 and CD8 T lymphocyte counts, 
and higher HIV mRNA levels (Aukrust et al., 1994; Godfried et al., 1994; Kulinkovich et 
al., 1992). Ryan et al. (2001) reported that higher levels of soluble TNF-alpha receptors 
in serum were correlated with the presence of cognitive impairment and brain atrophy on 
MRI scans in a sample of 28 individuals with HIV infection. Increased serum TNF-alpha 
was also noted in a sample of individuals with HIV encephalopathy as compared with 
HIV positive individuals without neurological disease (Grimaldi et al., 1991), and in 
samples of AIDS patients with dementia, vacuolar myeopathy, and sensory neuropathy as 
compared with AIDS patients without neurological disease (Wesselingh, Glass, 
McArthur, Griffm, & Griffin, 1994).
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Similar elevations in TNF-alpha have been observed in CSF fluid o f individuals 
with HIV infection as compared with HIV negative controls (Grimaldi et al., 1991; Tyor 
et al., 1992). However, these studies did not confirm the correlation between TNF-alpha 
levels and the presence of CNS disease.
Although some studies have demonstrated a positive correlation for IL-6 and IL-1 
with disease progression, the association was weaker than those demonstrated for TNF- 
alpha (Lathey, Kanangat, & Rouse, 1994; Martinez-Maza, 1992). Wesselingh et al. 
(1993) compared mRNA expression of various cytokines in the brains o f individuals 
diagnosed with and without HIV-related dementia. TNF-alpha levels were higher and IL- 
1 and IL-4 levels were lower in individuals with dementia, whereas no differences were 
noted in levels of IL-6, leukemia inhibitory factor, TGF-beta, or IFN-gamma mRNA 
expression.
Seilhean et al. (1997) examined the association between cognitive impairment and 
the extent of astrocytosis and TNF-alpha expression in specific brain regions (mid-frontal 
cortex, subcortical and deep white matter, and basal ganglia) in 12 individuals diagnosed 
with AIDS (8 who were diagnosed with dementia). Both density o f TNF-alpha 
expression and astrogliosis were positively correlated with severity of cognitive 
impairment.
IV Cortisol: Alterations in the circadian rhythm cycle of adrenal hormonal levels, 
both elevations and suppressions, have been described in HIV-infected individuals during 
all disease stages (Christeff et al., 1988; Kumar, Kumar, Morgan, Szapocznik, & 
Eisdorfer, 1993; Membrano et al., 1987; Villette et al., 1990), though in many individuals 
these changes may be subtle, not exceeding clinically defined ranges (Merenich,
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McDermott, Asp, Harrison, & Kidd, 1990). In a two-year longitudinal study, Findling et 
al. (1994) reported that relatively fewer patients showed overt cortisol abnormalities. 
However, a significant proportion of their sample of 53 patients (about 32%) exhibited 
elevations in plasma ACTH toward the end of their study, possibly reflecting the 
progression of subclinical adrenal dysfunction.
Relatively few studies have looked at the significance of HP A abnormalities on 
disease status separate from its affect on immune functioning. Lortholary et al. (1996) 
reported higher mean serum concentrations of cortisol in a sample of 23 men with AIDS 
(CDC stage IV) compared with 28 men with HIV infection that were asymptomatic or 
mildly symptomatic (CDC stage II and III). They also noted that CD4 T cell counts were 
inversely correlated with cortisol levels. Low levels of dehydroepiandrosterone (DHEA), 
a physiological antagonist of cortisol, have also been observed in individuals with HTV 
(Clerici et al., 1997b; Grinspoon & Bilezikian, 1992; Schifitto et al., 2000) and associated 
with advanced disease progression (Jacobsen et al., 1991; Mulder et al., 1992).
Summary
Individuals with HIV infection frequently report that the presence of somatic 
symptoms (especially chronic fatigue), neurocognitive impairments, and/or psychiatric 
difficulties adversely impacts their activities of daily living and quality of life. However, 
the pathogenesis of these symptoms is still poorly understood. A recent surge of research 
in psychoneuroimmunology has provided corroborative evidence for links between 
immune/HPA processes, mental status, and disease progression in various medical and 
psychiatric disorders. A high density of proinflammatory cytokine and cortisol receptors 
within the hypothalamus, medial temporal region, and frontal-subcortical systems
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suggests that these neural structures may be particularly sensitive to both systemic and 
localized fluctuations in these molecules. These brain regions are responsible for 
modulating a wide variety of physiological states, collectively referred to as “illness 
behaviour.” The physiological, neuropathological, and behavioural consequences arising 
from dysregulation of the immune/HP A system resembles some of the changes that 
accompany HIV. In vitro studies have yielded a better understanding of the contributions 
of immune and endocrine mediators to the pathogenesis of neurological insult in 
HIV/AIDS. However, the broader implications of these findings to the variability in 
clinical manifestations remains unclear. Although there continues to be a paucity of 
literature on the in vivo connections between specific mediators of biological processes 
and disease symptoms in HIV/AIDS, preliminary results summarized above suggest that 
elevated systemic concentrations of these molecules may be associated with disease 
progression and global measures of neurological functioning. More research is needed to 
determine the significance of alterations in immune and endocrine levels on specific 
neurocognitive, somatic, and depressive symptoms.
Study Objective and Predictions
This study was designed to expand upon previous research by exploring the 
associations between systemic indicators of immune and HP A activation, specific 
domains of cognitive impairment (as measured by neuropsychological test performance), 
fatigue, depression, and self-reported cognitive symptoms in adults with HIV/AIDS. The 
following main predictions are exploratory in nature, derived from the 
psychoneuroimmunological framework and previous research in other immune-mediated 
illnesses reviewed above:
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(1) Elevated proinflammatory cytokines (TNF-alpha and IL-6) and higher immune 
activation (neopterin) will be associated with:
(a) Poorer performance on all neuropsychological domains (attention/working
memory, learning efficiency, and psychomotor/processing speed)
(b) Higher levels of self-reported cognitive complaints (especially within the 
memory domain)
(c) Elevated depressive symptoms
(d) Increased fatigue
(2) Higher serum cortisol will be associated with:
(a) Poorer performance on measures of learning efficiency, possibly 
attention/working memory, but not psychomotor/processing speed
(b) Higher levels of self-reported cognitive complaints (especially within the 
memory domain)
(c) Elevated depressive symptoms
(d) Increased fatigue
(3) Elevated proinflammatory cytokines (TNF-alpha and IL-6), immune activation 
(neopterin), and cortisol levels will be associated with traditional biological indicators of 
disease status (i.e., lower CD4 T counts, higher CD8 T counts, and higher viral load).
Moreover, this study provides an opportunity to replicate research findings on the 
links between depression, fatigue, cognitive complaints, illness symptoms, and 
neuropsychological performance in an independent sample. The following corollary 
predictions were made based on recent research from the Neurobehavioural Research 
Unit at St. Michael’s Hospital:
(4) The symptom measures (i.e., depression, fatigue, cognitive complaints, and Illness 
symptoms) will be highly associated with each other.
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(5) Of the symptom measures, only cognitive complaints will be modestly associated 
with neuropsychological performance. In particular, self-reported cognitive symptoms 
will be modestly associated with the processing speed and working memory domains.




Forty adults with confirmed HIV infection and no past or current use of HAART 
medications (i.e., HAART-naive) took part in this study1. Given that antiretroviral 
medications are intended to alter viral and immune functioning, the HAART-naive 
participants were selected to reduce the possibility that the variability in biological 
measures may be confounded by medications or other infections accompanying disease 
progression. This study was approved by Research Ethics Boards at both St. Michael’s 
Hospital (SMH) and the University of Windsor. All participants provided written 
informed consent prior to their involvement in the study. Recruitment was conducted 
through the Neurobehavioural Research Program in HIV/AIDS at SMH in Toronto, ON 
by contacting physicians and posting flyers at HIV specialty clinics within the region. 
Interested individuals were screened to exclude those with pre-existing neurological 
conditions (e.g., CNS opportunistic infection, seizure disorder, or head injury with loss of 
consciousness exceeding 30 minutes), developmental problems (e.g., diagnoses of 
learning disability or attention deficit disorder), lower than a Grade 6 reading level, 
significant medical illness (e.g., recent heart attack, kidney disease, or liver failure), 
history of psychotic disorder, current intravenous drug use or treatment for substance 
abuse, or taking medication known to significantly alter adrenocortical function (e.g., 
prednisone, dexamethasone, fludrocortisone acetate, or cyclophosphamide). Nine
1 Fifty-five adults with confirmed HIV infection actually took part in this study. The HAART-naive participants are 
discussed in this paper. Preliminary findings for the sample o f  15 individuals on a stable HAART regimen for at least 1
l/2 years (i.e., HAART-stable) can be found in Appendix A.
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individuals were later removed from the analyses because they met one or more of the 
aforementioned exclusionary criteria.
Demographic data for the remaining sample (N -  31) are summarized in Table 5. 
The sample was comprised of 26 males (84%) and 5 females (16%). Participants were 
predominantly Caucasian (77%) and the majority reported sexual contact (90%) as a 
major risk factor for HIY infection. According to CDC disease stages classification 
(CDC: Centers for Disease Control and Prevention, 1992), 18 were asymptomatic (58%: 
CDC Al or A2), 9 were mildly symptomatic (29%: CDC B1 or B2), and 4 had AIDS- 
defining illnesses or a nadir CD4 count of less than 200 (13%: CDC A3, B3, or Cl-3).
The means and standard deviations for the biological indicators, symptom 
measures, and neuropsychological deficit scores are presented in Table 6. As a group, 
participants demonstrate mildly elevated symptom measures and mildly impaired 
neuropsychological test performance. Serum TNF-alpha and IL-6 concentrations for all 
individuals fell within the expected clinical reference ranges. Serum neopterin levels for 
9 participants were above the clinical cut-off (i.e., > 10 nmol/L) and clinically elevated 
semm cortisol levels were observed in 6 participants (i.e., > 375 nmol/L).
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Table 5
Demographics for HAART-naive sample (N =31)
Variables Mean (Standard Deviation)
Age (years) 35.6 (7.9)
Education (years) 13.4 (2.6)
WRAT reading (SS) 101.9 (9.8)
Recent CD8 Count 911.0(287.0)
Recent CD4 Count 541.6 (322.0)
Lowest CD4 Count 429.4 (220.3)
Recent Viral Load Log 3.9 (1.0)
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Table 6
Means and standard deviations o f the biological indicators, symptom measures, and 
neuropsychological deficit scores for the HAART-naive sample (N =31)
Variables Mean (Standard Deviation)
TNF-alpha mRNA 1149.0(604.4)
IL-6 mRNA 96.2(41.6)
TNF-alpha Elisa 8.5 (1.8)
IL-6 Elisa 0.6 (0.6)
Neopterin Elisa 8.3 (4.8)
Cortisol Elisa 280.9(100.9)
BDI Cognitive-Affective1 9.6 (7.0)
Piper Fatigue Total1 4.3 (2.1)
PAOF Total1 39.5 (21.1)




Processing Speed 0.48 (0.7)
-y
Working Memory/Attention 0.13 (0.3)
Learning2 1.45 (1.3)
I 'j
Raw scores; Composite deficit ratings
Note. BDI = Beck Depression Inventory; PAOF = Patient Assessment 
of Own Functioning Questionnaire
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Procedure
The entire research protocol took between 2 and 2 Vz hours, with testing and the 
blood draw completed on the same day. Participants were briefly interviewed to gather 
demographic information and then asked to complete questionnaires about subjective 
cognitive symptoms, depressive symptoms, physical symptoms, and fatigue. A battery of 
neuropsychological tests was selected to assess three domains commonly affected in 
individuals with HIV-associated cognitive impairment: (1) attention and working 
memory; (2) psychomotor efficiency and processing speed; and (3) learning efficiency 
and memory.
Participants were asked to abstain from drinking alcohol the evening before and to 
avoid eating any food and drinking caffeinated or soda beverages at least 1 Vz hours 
before their blood samples were drawn. Blood samples were scheduled to be collected 
between 10 am and 5 pm (with 80% completed between 10 am and 1:30 pm) to avoid 
confounding the results by the natural increase in cortisol production often observed 
during the early morning. Blood was drawn by medical personnel in the HIV specialty 
clinic at SMH, and then transported for analysis to laboratories at SMH and the 
University of Toronto (U of T). Written permission was also obtained to access routine 
laboratory results from their physicians.
Measures
Demographic background. A brief interview was used to gather information 
about sex, age, gender, and highest level of education. Screening questions about current 
and past medical conditions, psychiatric history, and drug use were asked to confirm that 
each participant met the inclusionary criteria described above.
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Disease status. Based on both CD4 T cell counts and symptomatology, the Center 
for Disease Control (CDC, 1992) provides a classification system for successive stages of 
HIV infection. Category A refers to individuals without any medical symptoms 
(asymptomatic) or minimally symptomatic (e.g., persistent generalized 
lymphadenopathy). Category B refers to symptomatic individuals with mild physical 
symptoms or minor opportunistic infections (e.g., oral candidiasis or herpes zoster). 
Category C refers to individuals who exhibit more serious infections or AIDS-defining 
illnesses (e.g., Pneumocystis carinii pneumonia, Karposi sarcoma or lymphoma, or 
wasting syndrome). Each of these categories is further divided into levels 1 through 3 
based on nadir CD4 T cell counts: (1) > 500 cells/mm3; (2) 200 to 499 cells/mm3; and (3) 
< 200 cells/mm3 (CDC, 1992). Individuals were classified according to CDC93 stages 
based on documented routine blood work results requested from the participant’s 
physician and the presence of HIV-related or AIDS-defining illnesses obtained through 
self-report in the interview.
Subjective symptoms. The Patient’s Assessment of Own Functioning Inventory 
(PAOF: Chelune et al., 1986) was used to assess subjective cognitive complaints. The 
PAOF is a self-report instrument that was “designed to elicit patients’ self-perceptions 
regarding the adequacy of their functioning in various everyday tasks and activities” 
(Chelune et al., 1986, p. 96). The questionnaire can be further subdivided into memory 
(10 items), language and communication (9 items), sensory-perceptual and motor skills 
(5 items), and higher level cognitive and intellectual functions (primarily executive-type 
skills; 9 items) domains. Participants are instructed to rate how often they experienced a 
particular kind of difficulty on a 6-point scale (0= almost never; 1= very infrequently; 2=
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once in a while; 3= fairly often; 4= very often; and 5= almost always). Total PAOF 
scores are calculated by adding the ratings on all 33 items, while domain scores are 
calculated by summing the ratings on the items comprising each domain. Higher scores 
indicate more self-reported cognitive symptoms.
The Beck Depression Inventory (BDI: Beck & Steer, 1993) was used to assess the 
presence and severity of depressive symptoms. The 21 items on this self-report 
questionnaire are graded on a scale from 0 to 3 to reflect increasing symptomatology. 
Standard clinical cut-offs for severity of depression have been defined: “minimal” (BDI < 
10), “mild” (BDI 10 to 16), “moderate” (BDI 17 to 29), and “severe” (BDI >29). Items 
can be further subdivided to obtain cognitive-affective (sum of items 1 to 13) and 
somatic-vegetative (sum of items 14 to 21) scores. Unless otherwise indicated, cognitive- 
affective scores were used in the analyses to avoid confounding the findings with somatic 
items that may reflect the effects of HIV infection rather than depression. Cognitive- 
affective scores of 10 or less show minimal symptoms of depression (i.e., “not 
depressed”), while scores greater than 10 are suggestive of “moderate” depression. Of 
note, the findings were consistent whether total or cognitive-affective scores were used in 
the analyses.
The degree of physical symptoms was obtained through a checklist of 20 non­
specific items (e.g., fever, dizziness, trouble sleeping, nausea, diarrhea, headache, skin 
rash, muscles aches/joint pain, weight loss, appetite reduction, and loss of sexual libido). 
Participants are asked to rate each item on a 5-point scale, indicating whether they have 
not experienced the symptom in the past month (0) or the degree to which the symptom
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has bothered them over the past month (l=not at all; 2=a little; 3=a lot; 4=terribly). 
Higher scores reflect the presence and severity of more physical symptoms.
Fatigue was measured using the Piper Fatigue Scale-Revised (PFS-R: Piper et al., 
1998). This instrument was designed and validated using a large sample of patients with 
cancer. The PFS-R consists of 22-items with each question rated along a 10-point scale. 
The total score also on a 10-point scale is obtained by summing all the items and dividing 
by 22. Factor analyses used in the development of the PFS-R suggest that the scale taps 
four dimensions: behavioural/severity (impact on activities and intensity), affective 
meaning (emotional attributions), sensory (energy attributions), and cognitive/mood 
(impact on thinking and feelings). Higher scores indicate an increased severity of fatigue 
and greater impact of fatigue on every day functioning.
Attention and Working Memory. Digit Span and Spatial Span, subtests of the 
Wechsler Memory Scale-Third Edition (Wechsler, 1997), were designed to assess 
auditory and visuospatial span/working memory, respectively. For Digit Span, the 
individual hears a series of progressively longer numbers and is required to repeat each 
series of numbers verbatim. Then, other number series are presented where the individual 
is required to provide the numbers in the reverse order. For Spatial Span, the individual is 
shown a board containing 9 blue-coloured blocks in a randomly spaced layout. The 
individual is required to copy the order of progressively longer sequences of blocks 
touched by the examiner, first in the same forward sequence as the examiner and then in 
the reverse sequence as the examiner.
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Psychomotor efficiency and Processing speed. In the Symbol Digit Modalities 
Test (SDMT: Smith, 1982), individuals are presented with a key that contains the 
numbers 1 to 9 paired with different symbols. The individual is required to fill in the 
corresponding numbers below a series of randomly ordered symbols as quickly as 
possible by using the pairings in the key. The Trail Making Test and Grooved Pegboard 
Test (GPT: Reitan & Wolfson, 1993) are components of the Halstead-Reitan 
Neuropsychological Battery. Trails Part A requires the individual to connect in order a 
series of numbers (e.g., 1 to 2 to 3...) randomly distributed over the page. The more 
complex Trails Part B requires the individual to alternate between connecting a number 
then a letter in their corresponding order (e.g., 1 to A to 2 to B...). The Grooved 
Pegboard Test involves psychomotor speed and dexterity in order to fit pegs into spaces 
of various angles on a board. Separate scores are obtained for both the individual’s 
dominant and non-dominant hands.
Learning efficiency and Memory. Verbal learning and memory was assessed by a 
word list task developed at the University of Southern California (Parker, Eaton, 
Whipple, Heseltine, & Bridge, 1995). The individual is orally presented with a list of 15 
semantically unrelated nouns at a rate of one word every 2 seconds, and required to recall 
as many words as they can in any order. The individual is given three learning trials with 
the words presented in different orders each time. After a 30-minute delay, they are also 
asked to recall as many words from the list and then to provide yes/no responses as a 
means to determine if they can recognize the words amongst distracters. A variety of 
outcome measures can be obtained from the profile of responses: (1) total correct 
responses; (2) number of perseverations or intrusions; (3) recall consistency across the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
57
three trials; (4) subjective organization; (5) serial position effects; (6) delayed recall; and 
(7) recognition hits/false positives.
The Ruff-Light Trail Learning Test (Ruff & Allen, 1999) was used to assess 
nonverbal learning and memory. The individual is presented with a series of 
interconnected circles, and instructed to draw a trail with their finger moving one circle at 
a time from the start to the finish. At each step, the individual receives feedback (“right” 
vs. “go back”) by the examiner in order to assist in learning the specified 15-step trail. 
The first time through is random (guided by the feedback), though more steps in the trail 
are expected to be learned with each successive attempt. Learning efficiency is measured 
by examining the number of trials required to learn the trail (maximum 10) and the 
number of step errors made on each trial. Recall of the trail is also assessed after a 60- 
minute delay period.
Composite deficit ratings. Performance on the neuropsychological tests in each of 
the four domains was summarized into a composite clinical deficit rating based on a 
modified application of Heaton’s Global Deficit Score (GDS). The validity of the GDS 
has been demonstrated in adults with HIV infection and has been described as a better 
measure than individual test scores, especially when investigating populations with 
“spotty” or subtle cognitive impairments (Carey et al., in press; Heaton et al., 1995). 
Individual T-scores on each of the tests were recoded according to the following 6-point 
scale: 0 = 40+ (normal), 1 = 35 to 39 (mild), 2 = 30 to 34 (mild to moderate), 3 = 25 to 29 
(moderate), 4 = 20 to 24 (moderate to severe), and 5 = less than 20 (severe). Composite 
deficit ratings for each domain were calculated by summing the recoded score for all tests 
comprising the domain and then dividing by the total number of tests. Attention/Working
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Memory was comprised of Digit Span and Spatial Span scores. Processing Speed 
included Trails A, Trails B, GPT dominant, GPT non-dominant, and SDMT. Learning 
was comprised of the total scores on trials 1 to 3 for the REMT and the total scores on 
trials 2 to completion of the RULIT. A Total deficit score was calculated by averaging all 
three o f the deficit domain scores. A cut-off o f 0.5 has been defined as the optimal 
balance between sensitivity and specificity in classifying individuals as normal versus 
impaired (Carey et al., in press). Higher deficit rating scores correspond with increased 
neuropsychological impairment.
Biological assays. Blood samples were collected in sodium citrate yellow top (8.5 
ml) and serum gel separator tiger top (2 x 7ml) vacutainer tubes by trained personnel at 
the HIV Specialty Clinic at SMH. Due to the light-sensitive nature of neopterin, the 
samples were immediately covered by foil and subsequently processed and stored in dark 
containers. The samples were delivered, in Saf-t-pak approved containers according to 
GCP guidelines, to the J. Alick Little Lipid Research Laboratory at SMH, Core 
Laboratory at SMH, and S. Der Research Laboratory at the U of T.
I. mRNA expression: Estimates of TNF-alpha and IL-6 mRNA expression were 
obtained by real-time quantitative polymerase chain reactions (PCR) procedures 
performed at the U of T lab. Peripheral blood mononuclear cells (PBMCs) were first 
isolated from the blood samples using Ficoll-Hypaque gradient centrifugation. RNA was 
extracted from lysed PBMCs and quantified using optical density 260/280 spectrometry 
(Eppendorf BioPhotometer). The quality of the mRNA sample was tested for degradation 
by polyacrylamide capillary gel electropheresis using Agilent Bioanalyzer 2100. PCR 
reactions were performed in a 3 84-well plate format using the ABI Prism 7900HT
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Sequence Detection System. cDNA was prepared by reverse transcription using 2ug of 
RNA according to standard procedures. Real-time PCR amplification was conducted 
using 10 ng of the reverse transcribed cDNA. The primers used in the procedure were 
designed within the U of T laboratory:
( 1 )  HsTNFa-317/383 - AGCTGCCTTGGCTCAGACAT /  GCTACATGGGAACAGCCTATTGT
(2) HsIL6-59/134 - CACTGGGCACAGAACTTATGTTG / AAAATAATTAAAATAGTGTCCTAACGCTCAT 
Quantification procedures were performed in triplicate for each sample. Results represent 
the average estimated copies of mRNA for each participant.
II. Serum protein concentrations: The blood samples were immediately separated 
by centrifuge, and the plasma was aliquoted, coded, and stored at -70° until assayed. 
Serum concentrations of IL-6, TNF-alpha, and neopterin were obtained by trained 
laboratory technicians in the Lipid laboratory using commercial enzyme-linked 
immunosorbant assays (ELISA) kits according to manufacturer guidelines (BioSource 
International & IBL Hamburg). Serum cortisol concentrations were assessed by 
commercial radioimmunoassays in the SMH Core Laboratory according to manufacturer 
directions. The following normative reference ranges were provided: IL-6 (0.100 pg/ml 
to 10.73 pg/ml), TNF-alpha (< 20 pg/ml), neopterin (< 10 nmol/L), and cortisol (80 
nmol/L to 375 nmol/L).
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CHAPTER III 
Results
All statistical analyses were conducted using SPSS® for windows version 10 with 
statistical significance defined as p  < .05. One-tailed analyses were used because of the 
directionality inherent in the hypotheses. Graphical and statistical diagnostics were used 
to detect the presence of univariate or multivariate outliers, significant deviations from 
normality, nonlinearity or heteroscedasticity (Tabachnick & Fidell, 1996). One outlier 
(i.e., score < 3 standard deviations) was removed from the TNF-alpha mRNA analyses 
due to its unduly influence on the results. The neuropsychological deficit scores and some 
of the biological assays (TNF-alpha mRNA, IL-6 Elisa, and neopterin) were positively 
skewed with many individuals scores within the normal range (i.e., lower values). 
Transformations were not used in the analyses because the application of common 
transformations to these variables did not significantly alter the distribution and the 
interpretation of transformed measures is often unclear. Instead, results of nonparametric 
tests or distribution-free tests were compared to those on parametric tests. As similar 
patterns of findings were seen, the nonparametric results will be summarized below for 
continuity among analyses with any major deviations highlighted.
Performance on neuropsychological deficit indices
Most individuals performed within the mildly impaired to average ranges as 
determined by total and domain-specific deficit ratings (see Table 7). The working 
memory index had the most restricted range of performance, while learning efficiency 
showed the most variability. This must be taken into account when examining the 
meaning of subsequent analyses, whether parametric or non-parametric, as the findings 
may be limited by skewness and restricted range of values (Howell, 1999). The
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intercorrelations between the neuropsychological deficit ratings are presented in Table 8. 
All domain deficit ratings were correlated with each other (p < .05), with the exception of 
the learning efficiency and working memory/attention deficit ratings.
Associations between symptom measures
Spearman correlations were calculated to examine the relations among the various 
symptom measures (see Table 9). Consistent with other studies, higher depression scores 
were moderately correlated with the endorsement of more illness symptoms (p < .01). 
Elevated depression scores were also modestly related to increased fatigue and total 
subjective cognitive symptoms (p < .05). Fatigue and self-report of cognitive symptoms 
were strongly correlated (p < .001) and illness symptoms were moderately associated 
with both fatigue and total cognitive complaints (p < .01).
Associations between the various biological indicators
Spearman correlations were calculated to explore the relations among the various 
biological measures (see Table 10). As predicted, the measures of proinflammatory 
cytokine Elisa assays (IL-6 and TNF-alpha) were positively correlated (p  < .01). 
However, the mRNA expression of the proinflammatory cytokines was not associated. 
Contrary to expected, mRNA cytokine serum protein concentrations were not correlated 
with the corresponding estimated cytokine mRNA expression. Higher immune activation 
as estimated by elevated neopterin levels was associated with higher recent viral loads (p 
< .01) and lower recent CD4 T cell counts (p < .05), but not correlated with elevations in 
recent CD8 T cell counts (p — .16). Interestingly, higher serum cortisol levels were 
associated with lower CD4 T ceil counts (p < .05).
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Table 7
Frequencies o f individuals within impairment ranges across total and domain-specific
neuropsychological deficit indices within the HAART-naive sample (N — 31)
Total Processing Working Learning
Speed Memory Efficiency
Level o f Impairment n (%) n (%) n (%) n (%)
Average 15 (48) 22 (71) 26 (84) 7 (23)
Mild 11 (36) 6 (19) 5 (16) 11 (36)
Mild to Moderate 5 (16) 2 (7) 0 (0) 5 (16)
Moderate 0 (0) 1 (3) 0 (0) 4 (13)
Moderate to Severe 0 (0) 0 (0) 0 (0) 3 (10)
Severe 0 (0) 0 (0) 0 (0) 1 (3)
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Table 8
Spearman correlations (rs) showing the association between the total and domain- 
specific neuropsychological deficit ratings within the HAART-naive sample (N -  31)
Total Processing Working Learning
Speed Memory Efficiency
Total 1.00
Processing Speed 0.76*** 1.00
Working Memory/Attention 0.55*** 0.51** 1.00
Learning Efficiency 0.85*** 0.42** 0.20 1.00
**p < .01 (1-tailed), ***p < .001 (1-tailed)
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Table 9
Spearman correlations (r<) showing the association between various symptom measures
within the HAART-naive sample (N = 31)
Depression Fatigue Cognitive Memory Illness
Total
BDI Cognitive-Affective 1.00
Piper Fatigue Total 0.39* 1.00
PAOF Total 0.34* 0.73*** 1.00
PAOF Memory 0.21 0.64*** 0.87*** 1.00
Illness symptoms 0.52** 0.53** 0.42** 0.30
*p < .05 (1-tailed), **p< .01 (1-tailed)
Note. BDI -  Beck Depression Inventory; PAOF=Patient Assessment of Own Functioning
Questionnaire
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
65
Table 10
Spearman correlations (r j showing the association of the biological indicators within













Recent CD8 0.08 0.20 -0.17 0.06 0.24 0.14
Recent CD4 -0.03 0.18 0.18 -0.04 -0.41* -0.38*
Recent Viral Load -0.16 0.05 -0.09 -0.13 0.52** 0.29
IL-6 mRNA 0.24 1.00
TNF-alpha Elisa 0.03 0.23 1.00 ----- ------ -----
IL-6 Elisa -0.12 -0.08 0.46** 1.00 ------ -----
Neopterin Elisa 0.05 0.01 0.28 0.16 1.00 -----
Cortisol Elisa -0.31 -0.29 -0.18 -0.03 0.16 1.00
*p < .05 (1-tailed), **p< .01 (1-tailed)
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Associations between symptom measures and neuropsychological performance
The Spearman correlation coefficients for neuropsychological deficit ratings 
across various symptom measures are presented in Table 11. Similar to previous research, 
depressive symptoms and illness symptoms were not associated with neuropsychological 
performance. Aside from the working memory/attention deficit score, neuropsychological 
deficit ratings were also not associated with fatigue and cognitive complaints. Lower 
working memory/attention deficit scores were, however, modestly associated with higher 
fatigue (p < .01) and self-reported cognitive symptoms (p < .05).
Associations between biological indicators and neuropsychological performance
In order to examine the relation between biological measures and 
neuropsychological functioning, Spearman correlation coefficients were calculated 
between the neuropsychological deficit ratings, cytokine serum concentrations, cytokine 
mRNA expression, serum neopterin, and serum cortisol levels. Contrary to the 
hypothesis, no consistent pattern of associations was found between the biological 
indicators and neuropsychological performance (refer to Table 12).
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Table 11
Spearman correlations (r j showing the association between various symptom measures




Total -0.18 -0.21 -0.19 -0.17 -0.13
Processing Speed 0.03 -0.25 -0.21 -0.21 -0.01
Working Memory/Attention -0.04 -0.37* -0.44** -0.36* -0.04
Learning Efficiency -0.30 -0.08 -0.01 0.00 -0.20
*p < .05 (1-tailed), **/?< .01 (1-tailed)
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Table 12
Spearman correlations (rj showing the association o f the biological indicators and 
measures o f  depression, fatigue, illness symptoms, cognitive symptoms, and cognitive 













BDI Cog-Aff1 0.12 0.40* 0.13 0.18 0.28 -0.04
Piper Fatigue Total1 -0.13 0.38* 0.04 0.13 0.07 -0.05
PAOF Total1 0.00 0.21 -0.12 -0.16 0.15 -0.19
PAOF Memory1 0.02 0.28 -0.16 -0.35* 0.16 -0.10
Illness Total1 -0.23 0.16 -0.19 0.24 0.06 0.06
Total2 0.18 -0.04 -0.12 0.00 0.11 -0.23
Processing Speed2 0.18 -0.06 -0.06 0.08 0.02 -0.23
WM/Attn2 -0.02 -0.06 -0.32* -0.11 -0.17 -0.06
Learning2 0.07 0.01 -0.14 -0.10 0.20 -0.12
1 2 • •Raw scores; Composite deficit ratings
*p < .05 (1-tailed), **p< .01 (1-tailed)
Note. BDI Cog-Aff = Beck Depression Inventory Cognitive-Affective score; PAOF = 
Patient Assessment of Own Functioning Questionnaire; WM/Attn = Working Memory 
and Attention
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Associations between biological indicators and symptom measures
Spearman correlations between the six biological measures, depressive symptoms 
(BDI cognitive-affective), fatigue (PFS-R total scores), subjective cognitive symptoms 
(PAOF total and memory scores), and total illness symptoms (HIV symptom checklist) 
are summarized in Table 12. As predicted from the literature, higher depressive 
symptoms were modestly associated with elevated IL-6 mRNA expression (p < .05). 
Modest positive correlations were also noted for IL-6 mRNA expression and fatigue (p < 
.05). A similar pattern of findings was obtained with the Pearson product-moment 
correlations, though the associations between the biological indicators and symptom 
measures were stronger. This may partly reflect the fact that nonparametric tests have 
lower power relative to the corresponding parametric test (Howell, 1999). The Pearson 
correlational analyses showed that IL-6 mRNA expression was correlated with all 
symptom measures, including depression (r = 0.50, p < .01), fatigue (r = 0.33, p  < .05), 
total cognitive complaints (r = 0.32, p < .05), memory complaints (r -  0.31,p  < .05), and 
illness symptoms (r = 0.34, p  < .05). Higher serum neopterin was also associated with 
elevated depressive symptoms (r = 0.33,p  < .05).
Given the high intercorrelations between symptom measures, partial correlations 
were used to further tease apart the relations with IL-6 mRNA expression. When the 
influence of depression was controlled, IL-6 mRNA expression was no longer correlated 
with fatigue (pr = 0.19, p  = .174), illness symptoms (pr = 0A0,p  = .31), total cognitive 
complaints (pr -  0.18,/? -  .19), or memory complaints (pr = 0.21, p -  .08). Inversely, the 
association between depression and IL-6 mRNA expression weakened but remained 
statistically significant after removing the influences of fatigue, total cognitive 
complaints, and illness symptoms (pr = 0.39, p  < .05).
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A s s o c ia tio n s  be tw een  severity o f depression a n d  IL-6 mRNA and neopterin levels
Individuals were grouped according to the severity of their depression in order to 
clarify the relation between depressive symptoms, IL-6 mRNA expression, and serum 
neopterin levels. In order to capture the range of severity, groups were d e f i n e d  according 
to standard clinical cut-offs on the total BDI score (Beck & Steer, 1993): “minimal” (BDI 
< 10), “mild” (BDI 10 to 16), “moderate” (BDI 17 to 29), and “severe” (BDI >29). 
Participants’ concentrations of IL-6 mRNA a n d  neopterin divided across the four levels 
of depression a r e  shown in Figures 3 and 4. Although the small number of individuals in 
each group limits the generalizability of these findings, some interesting patterns can be 
seen. All of the severely depressed individuals showed high IL-6 mRNA expression (i.e., 
above 125 copies/lOng of c-DNA) and high neopterin levels (i.e., close to or above the 
clinical cut-off of 10 nmol/L).
One-way ANOVAs verified that differences existed between depression severity 
subgroups for both IL-6 mRNA expression [F(3, 24) -  7.72, p  < .001] and serum 
neopterin concentrations [F(3, 26) = 3.39, p  < .05]. Pairwise multiple comparisons were 
completed to specifically determine which of the groups’ means differed from each other. 
The Bonferroni method, which assumes equal variances (supported by non-significant 
Levene statistics), was selected to adjust for inflation of Type I error rate with multiple 
comparisons. The severely depressed individuals had higher mean IL-6 mRNA 
expression compared with the means for the moderate (p  < .01), mild (p < .01), and 
minimally (p < .001) depressed groups (see Figure 5). The severely depressed individuals 
had higher mean serum neopterin levels compared with the means for mild (p < .05) and 
m in im ally (p <.05) depressed groups, but w a s  not different f r o m  the mean of the 
moderately depressed group (see Figure 6).
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Figure 3. Scatterplot showing IL-6 mRNA expression for individual participants divided 
according to the severity of their depressive symptoms.
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Figure 4. Scatterplot showing serum neopterin concentrations for individual participants 
divided according to the severity of their depressive symptoms.
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Figure 5. Mean IL-6 mRNA expression as a function of depression severity.
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Figure 6. Mean serum neopterin concentrations as a function of depression severity.
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Potential confounding influences on the biological measures
Interactions with antidepressant medications. The influence of antidepressants 
on the association between IL-6 mRNA expression, serum neopterin, and depression was 
explored by grouping participants into those currently using antidepressants (n -  18) and 
those not taking any antidepressants (n = 13). All types of antidepressants (e.g., tricyclics 
and selective serotonin reuptake inhibitors) were considered together given the small 
sample size. Means and standard deviations for age, education, estimated reading level, 
blood indicators, biological measures, and symptom measures for the separate 
antidepressant groups are provided in Table 13. No differences were evident between the 
individuals taking and not taking antidepressants on the demographic variables, with the 
exception of the mean age for the antidepressant group being slightly higher than the 
mean age of those not taking any antidepressants [F (1, 29) = 4.33, p  < .05]. Mean 
biological indicators and symptom measures were not different for participants taking 
versus not taking antidepressants.
Given the reduced power associated with nonparametric tests and the small 
sample sizes, both Pearson (r) and Spearman (rs) correlations between depressive 
symptoms (BDI cognitive-affective scores), IL-6 mRNA expression, and serum neopterin 
levels are separately calculated for the antidepressant groups. Depressive symptoms and 
IL-6 mRNA expression remained modestly associated for both the antidepressant (rs = 
0.32,p  = .14; r = 0.60, p  < .05) and no antidepressant groups (rs -  0.45, p < .05; r = 0.39, 
p  = .08). On the other hand, an interesting interaction was observed for neopterin serum 
concentrations and depressive symptoms across antidepressant groups. Although 
neopterin and depressive symptoms were strongly associated in the antidepressant group
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(rs = 0.83, p  < .001; r  = 0.78, p < .001), the association was nullified in the group not 
taking any antidepressants (rs = -0.25, p > .05; r — -0.08, p  > .05). These findings are 
graphically illustrated by the scatterplot in Figure 7.
In order to further investigate the nature of this interaction, individuals were 
divided into not depressed and depressed groups based on a BDI cognitive-affective cut­
off score of 10 (Beck & Steer, 1993). Participants’ concentrations o f IL-6 mRNA and 
neopterin for depressed versus non-depressed individuals are separately shown by 
antidepressant groups in Figures 8 and 9. Despite the small number o f individuals in each 
group, some interesting patterns are evident. For individuals taking antidepressants, 
variability in IL-6 mRNA expression was apparent for both depressed and not depressed 
individuals. Although variability was also apparent among individuals not taking 
antidepressants, a greater proportion of depressed as compared with non-depressed 
individuals had higher levels of IL-6 mRNA expression. Depressed individuals taking 
antidepressants showed relatively higher neopterin serum concentrations in comparison 
with non-depressed individuals taking antidepressants. In fact, all six depressed 
individuals on antidepressants were above the clinical reference range for neopterin (i.e., 
cut-off >10 nmol/L) while all seven non-depressed individuals on antidepressants were 
within normal expectations. More variability was seen among both the depressed and 
non-depressed individuals not on antidepressants, though the majority (80%) of 
individuals not taking antidepressants had serum neopterin levels within normal limits.
ANOYAs separately performed by antidepressant group provided further support 
for an interaction between depression, antidepressants, and neopterin levels. Although 
mean neopterin levels of the depressed and non-depressed groups were not different for
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those not taking antidepressants [F(l, 15) = 0.00, p  > .05], mean neopterin levels were 
higher in the depressed as compared to non-depressed group for those taking 
antidepressants [F(l, 11) = 45.66,p  < .001] (see Figure 10).
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Table 13
Demographic data, biological indicators, and symptom measures for HAART-naive 







Age (years)* 38.8 (9.0) 33.2 (6.3)
Education (years) 13.3 (2.6) 13.5 (2.6)
WRAT reading (SS) 101.9 (9.6) 101.9 (10.3)
Recent CD 8 Count 941.4 (331.0) 873.8 (236.3)
Recent CD4 Count 593.5 (360.5) 499.4 (292.2)
Lowest CD4 Count 453.6 (248.2) 412.4 (204.5)
Recent Viral Load Log 4.0 (0.9) 3.7 (1.0)
TNF-alpha mRNA 961.8 (373.3) 1298.7(717.5)
IL-6 mRNA 103.7 (48.8) 89.7 (34.7)
TNF-alpha Elisa 8.8 (1.0) 8.2 (2.2)
IL-6 Elisa 0.7 (0.5) 0.6 (0.8)
Neopterin Elisa 8.8 (4.6) 7.9 (5.0)
Cortisol Elisa 265.8 (87.8) 292.5(111.1)
BDI Cognitive-Affective 9.2 (8.2) 9.9 (6.1)
Piper Fatigue Total 4.6 (1.1) 4.0 (2.7)
PAOF Total 39.9 (18.7) 39.2 (23.3)
PAOF Memory 15.0(8.0) 15.1 (8.7)
Illness Total 23.2 (9.8) 26.4 (11.4)
* p  < .05 (Means differ for two groups)
Note. BDI- Beck Depression Inventory; PAOF = Patient Assessment o f Own 
Functioning Questionnaire
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Figure 7. Scatterplot showing the relations between depressive symptoms and serum 
neopterin levels separated by antidepressant groups.
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Figure 8. Scatterplots showing the relations between depressive symptoms and IL-6 
mRNA expression separated by antidepressant groups.
Note. No = individuals not taking any antidepressant medication, Yes = individuals 
taking antidepressants
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Figure 9. Scatterplots showing the relations between depressive symptoms and serum 
neopterin levels separated by antidepressant groups.
Note. No = individuals not taking any antidepressant medication, Yes = individuals 
taking antidepressants
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
0.00
Minimal Depressed
D e p re s s iv e  S y m p to m s
Minimal Depressed
D e p re s s iv e  Symptoms
Figure 10. Mean serum neopterin concentrations for depressed and non-depressed 
individuals separated by antidepressant groups.
Note. No = individuals not taking any antidepressant medication, Yes = individuals 
taking antidepressants
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Sex. Differences in production and cyclic regulation of hormones between the 
sexes could potentially influence the biological measures. In particular, cortisol levels can 
be suppressed by the presence of other hormones which considerably vary over the 
month in females. Although there are too few female participants to analyse sex as 
separate groups, the association between biological assays and symptom measures was 
examined with the 5 female participants removed from the sample. Taking into 
consideration the reduction in power due to fewer participants overall, the pattern of 
results essentially remains unchanged. IL-6 mRNA expression was correlated with all the 
symptom measures: BDI cognitive-affective (rs — 0.54, p  < .01; r — 0.57, p  < .01), Piper 
Fatigue Scale (rs = 0.51, p  < .01; r = 0.44, p  < .05), PAOF total (rs — 0.38, p  < .05; r = 
0.39, p < .05), PAOF memory (rs = 0.43, p < .05, r = 0.42, p  < .05), and to a lesser extent 
with HIV symptom checklist {rs -  0.29, p  = .09; r -  0.43, p  < .05). A more modest 
association was present between serum neopterin levels and depressive symptoms (rs ~
0.26, p  = .1; r  = 0.37, p  < .05), though neopterin and depressive symptoms remained 
strongly correlated in the group of individuals taking antidepressants (rs -  0.80, p  < .001; 
r = 0.75, p  < .01). The correlation coefficients for the other biological indicators 
(including serum cortisol) with symptom measures and neuropsychological deficit ratings 
were non-significant.
Disease stage. Severity of d i s e a s e  progression could also potentially impact the 
biological measures. Although the majority of individuals in the HAART-naive group 
were asymptomatic (n -  18, 58%) or mildly symptomatic in = 9, 29%) as defined by 
CDC93 staging criteria, 4 individuals had AIDS-defining illnesses or a nadir CD4 count 
of less than 200. The correlational analyses were rerun without the four individuals at
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advanced stages. IL-6 mRNA expression remained associated with scores on the BDI 
cognitive-affective (rs = 0.45, p  < .01; r = 0.53, p < .01) and to a lesser degree with the 
Piper Fatigue Scale (r, = 0.40, p  < .05; r -  0.39, p < .05), PAOF total (rs = 0.24, p  = .13; r 
= 0.34,/? = .05), PAOF memory (rs = 0.28,/? = .09; r = 0.37,/? < .05), and HIV symptom 
checklist (r5 = .19,/? = .18; r = 0.36,/? < .05). In contrast, the association between serum 
neopterin and BDI cognitive-affective scores was weakened and no longer statistically 
significant (rs = 0.20, p  = .16; r = 0.27, p = .09) when the participants with AIDS were 
removed. This may stem, in part, from the reduced sample size, decreased variability in 
neopterin values, as well as the influence of the AIDS individuals, as three out of the four 
participants with AIDS had elevated serum neopterin levels outside the normal reference 
range (see Figure 11). However, the association between neopterin and depressive 
symptoms remained strongly correlated in the group of individuals taking antidepressants 
(rs -  0.88,/? < .001; r = 0.84,/? < .001).
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Figure 11. Scatterplot showing serum neopterin levels across disease stage.
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CHAPTER IV 
Discussion
Traditionally, neuropsychology has been concerned with explaining human 
behaviour in terms of central nervous system (CNS) functioning (i.e., defining brain- 
behaviour relationships). Recent work in the field of psychoneuroimmunology provides 
mounting support for integral connections between systemic biological processes 
(immune and endocrine) and key brain systems responsible for governing a wide variety 
of physiological and behavioural responses including affect and cognition. Transient 
elevations in biological mediators (cytokines and hormones) are pivotal for instigating 
physiological responses that permit adaptation to environmental changes including 
physical (e.g., acute infection) and psychological stressors (e.g., perceived threats). 
“Illness or sickness behaviours” consequently arise as the body redistributes resources 
and actively fights acute infections: fever, malaise, fatigue, depressed mood, decreased 
appetite, accelerated weight loss, increased need for sleep, reduced sex drive, increased 
sensitivity to pain, and reduced cognitive efficiency. While adaptive in the short-term, 
chronic dysregulation of biological processes and associated prolongation of “illness 
behaviours” could significantly impede an individual’s ability to function in everyday 
life.
“Illness behaviours” resemble the somatic, affective, and cognitive symptoms 
often accompanying various medical conditions, including those frequently present in 
individuals with HIV/AIDS. As a result of remarkable advancements in antiretroviral 
drug therapies over the past 20 years, many individuals are now living and coping with 
HIV as a chronic illness. Although medications have effectively slowed disease
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progression, symptoms of chronic fatigue, depression, and cognitive difficulties remain 
prevalent and often adversely impact quality of life. Management of these clinical 
symptoms can be challenging given the complexity of potential factors (both biological 
and psychological) that may underlie the differential expression across individuals. While 
immune and endocrine dysfunction in HIV has been well-described at a cellular 
pathophysiological level, there remains a paucity of literature examining the possible 
links between these biological alterations and the development of specific clinical 
symptoms.
This pilot study aimed to integrate biological studies on the neuropathogenesis of 
HIV within a broader clinical context by exploring the associations of systemic indicators 
of immune system (neopterin, IL-6, and TNF-alpha) and HPA axis (cortisol) activation 
with the presence and severity of the following clinical symptoms in a sample of 31 
HAART-naive participants with HIV infection: (1) specific domains of cognitive 
impairments as measured by performance on neuropsychological tests (attention/working 
memory, learning efficiency, and psychomotor/processing speed); (2) self-reported 
cognitive symptoms; (3) a subjective measure of fatigue; and (4) self-reported depressive 
symptoms.
Evaluation o f Predictions and Study Limitations
Hypothesis 1. The first prediction was only partially supported in this pilot 
investigation. While immune markers were not correlated with objective measures of 
cognitive impairment in the present study (Hypothesis la), associations were obtained 
between some immune markers and subjective symptom measures (Hypotheses lb to d).
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I. Symptom measures: Elevated immune activation (as measured by serum 
neopterin levels and mRNA expression of the proinflammatory cytokine IL-6) was 
associated with depressive symptoms. Higher serum IL-6 mRNA expression was also 
modestly associated with elevated fatigue, total and memory cognitive complaints, and 
illness symptoms, though only the relation with depression remained significant after the 
overlapping influences of the other symptom measures were removed. More specifically, 
both the presence and severity of depressive symptoms were related to elevated immune 
activation, such that the most severely depressed individuals in this sample showed 
higher levels o f IL-6 mRNA expression and neopterin concentrations. Similarly, several 
recent investigations have shown links between depression and immune activation, as 
measured by both elevated serum IL-6 and neopterin in depressed individuals (e.g., 
Bonaccorso et al., 1998; Musselman et al., 2001; Schlatter et al., 2004; Trzonkowski et 
al., 2004; Zautra et al., 2004). In general, studies comparing patients diagnosed with 
Major Depressive Disorder (with or without comorbid medical conditions) versus non- 
depressed individuals have found group differences in mean levels of serum immune 
measures, whereas relatively fewer studies have found an association between biological 
measures and the severity of depression (see Table 3). While condition/control group 
differences are initially useful in identifying measures of interest to study, they provide 
limited information about the individual variability in symptom expression within a 
medical condition. More in-depth exploration of factors within a specific condition is 
necessary for identifying subgroups and associated characteristics that may place 
particular individuals at higher risk for the development of certain clinical symptoms.
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In the present study, the effects of antidepressant medication on the link between 
immune activation and depressive symptoms was explored. Although no association was 
evident in the individuals not taking antidepressants, neopterin and depressive symptoms 
were strongly associated in the group of individuals currently taking antidepressants. In 
the antidepressant group, some of the individuals showed both reduced depressive 
symptoms and lower neopterin levels, suggesting that the antidepressant medications 
were effective. In contrast, a subsample of individuals on antidepressants continued to 
endorse high levels of depressive symptoms and had elevated neopterin levels. This 
subsample may represent individuals not responding to the treatment similar to 
previously described treatment-resistant groups (Kubera et al., 2004; Lanquillon et al., 
2000). Both Xia et al. (1996) and Maes et al. (1999) have demonstrated 
immunosuppressive effects of antidepressants in vitro using serum from healthy adults. In 
contrast, most in vivo studies have failed to show significant changes in immune markers 
with short-term (< 3 months) antidepressant treatment in inpatient or acutely depressed 
samples (see Table 4). Many individuals require long-term treatment with antidepressants 
to achieve desired prolonged effects. Although data on the duration of antidepressant 
treatment was not systematically collected in the present study, the available information 
suggests that many individuals in the present sample had been taking the antidepressants 
much longer than 3 months. Moreover, mean change scores used in previous 
investigations may obscure individual differences in biological markers, whereas the 
consideration of each individuals’ post-treatment levels relative to standard clinical cut­
offs in the present study permitted the isolation of subsamples within the antidepressant 
group (see Figure 9). Similarly, when Lanquillon et al. (2000) examined treatment
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responders and non-responders separately, a decline in some immune markers was 
apparent but only for the individuals who were responding to the antidepressant at 6 
weeks.
II. Cognitive im pairm ent. Contrary to expected, no consistent pattern o f 
association was found between the biological indicators and neuropsychological 
performance across total, attention/working memory, learning efficiency and memory, 
and psychomotor/processing speed deficit ratings in the present sample. Several potential 
explanations may be offered for the absence of this association. Although the HIV virus 
has been shown to enter the CNS within days to weeks of infection (e.g. Davis et al., 
1993; Resnick et al., 1988), cognitive impairments are rarely evident at diagnosis and 
increase in prevalence with duration of the illness and advancing disease stage (Bomstein 
et al., 1993; White et al., 1995). Research on the cellular mechanisms underlying 
neurotoxicity suggest that the HIV virus does not directly infect neurons but instead is 
stored and transported to the brain via macrophages. The release of viral and cellular 
toxins (e.g., proinflammatory cytokines or oxygen radicals) from chronic low-grade 
activation of macrophages is thought to indirectly damage the CNS (e.g., Gendelman et 
al., 1994; Minagar et al., 2002). Given the complexity and resilience of the brain, 
multiple insults exacerbated by transient states of heightened immune activation (that 
also perpetuate phases of more intense viral replication) may be required prior to showing 
significant cognitive impairments as measured by below expected performance on 
neuropsychological tests. As such, measurement of an individual’s biological status at a 
single time-frame may not accurately correlate with the damage already done to the CNS. 
While transient fluctuations in proinflammatory cytokines and immune activation may
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contribute to the mild, intermittent cognitive inefficiency experienced in every day life, a 
single session of objective neuropsychological tests may not capture these subtle 
subjective cognitive changes as individuals may be able to compensate within the testing 
session. Neuropsychological testing provides an estimate of the individual’s best 
cognitive performance within an isolated and time-limited context. However, this 
performance may be unrepresentative of the ongoing demands faced in everyday 
situations especially in individuals with relatively mild changes in their cognitive 
abilities. On the other hand, more stable or chronic elevations in biological indicators of 
immune activation may accompany further deterioration of immune system functioning 
at advanced disease stages (e.g., Aukrust et al., 1994; Baier-Bitterlich et al., 1996; 
Kulinkovich et al., 1992). This may account for why a few studies have found 
associations between elevated immune activation (in particular neopterin and TNF-alpha) 
and more frank neurological impairment or dementia (Ryan et al., 2002; Seilhean et al., 
1997), HIV encephalopathy (Grimaldi et al., 1991), as well as the presence of 
neurological diseases, such as meningitis, CNS opportunistic infections, and 
inflammatory demyelinating polyneuropathies (Griffin et al., 1991; Wesselingh et al., 
1994) in patients diagnosed with AIDS.
Another possibility could be that a more modest association was obscured due to 
the size and characteristics of the present sample. While the sample size is adequate to 
detect a moderate or strong correlation, a much larger sample size (N > 150) may be 
needed to detect a more modest association (Howell, 1999). Although some preliminary 
studies (e.g., Kirschbaum et al., 1996; Kozora et al., 2001; Reichenberg et al., 2001; 
Spath-Schwalbe et al., 1998) with similar sample sizes have obtained modest correlations
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between biological indicators and cognitive impairments in other medical conditions or in 
healthy individuals under experimental manipulations (see Table 2), larger samples of 
adults with HIV infection may be needed given the demographic and clinical variability 
in this population. For example, other studies have required large sample sizes in order to 
capture small but clinically significant relations between neuropsychological performance 
and subjective cognitive complaints in samples of adults with HIV infection (e.g., Carter 
et al., 2003; Rourke et al., 1999a).
In addition to suppressing viral replication, initiation of antiretroviral medications 
may be accompanied by reductions in biological indicators of immune activation such as 
neopterin (e.g., Amirayan-Chevillard et al., 2000; Zangerele et al., 2002). Opportunistic 
infections, more frequently present with advanced disease progression, may alter immune 
status and cytokine profiles (e.g., Valdez et al., 1997-1998). HAART-naive participants 
were specifically selected to reduce these potential confounds. Physicians typically 
initiate HAART treatment when CD4 T cell counts significantly drop (often below 200) 
and symptoms ensue. Hence, the majority of the HAART-naive sample were 
asymptomatic (58%) and mildly symptomatic (21%) according to CDC disease stage 
classification criteria (CDC, 1992). Hence, the manifestation of clinical symptoms in the 
present sample may have been reduced by this selection bias. The restricted variability in 
neuropsychological test performance and biological measures (i.e., most scores within 
normal limits) may have contributed to the limited findings.
Hypothesis 2. Higher serum cortisol was not associated with poorer performance 
on the neuropsychological measures, higher self-reported cognitive complaints, elevated 
depressive symptoms, nor increased fatigue in the present sample. These findings are
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contrary to previous studies (cited in Tables 1, 2, and 3) showing associations between 
elevated cortisol and higher fatigue, depressive symptoms, and impaired cognitive 
function. The link between elevated cortisol and impaired cognitive function (in 
particular on measures of verbal declarative memory) has been consistently demonstrated 
using experimental manipulations (corticosteroid administration or exposure to 
psychosocial stressor) in healthy participants (e.g., Kirschbaum et al., 1996; Newcomer et 
al., 1999). Higher cortisol levels have also been associated with cognitive impairment, 
depression, or fatigue in medical conditions that have significant alterations in adrenal 
functioning due to the disease process itself (e.g., Cushing’s syndrome, early withdrawal 
of alcoholics, or Alzheimer’s disease), treatment with corticosteroids (e.g., rheumatoid 
arthritis), or under conditions of dexamethasone suppression (e.g., Major Depressive 
Disorder) (e.g., Errico et al., 2002; Keenan et al., 1995; Mauri et al., 1993; Starkman et 
al., 1992; Van Loden et al., 1998; Umegaki et al., 2000; Weiner et al., 1997; Wolkowitz 
et al., 1990). While alterations in the circadian rhythm cycle o f adrenal hormonal levels 
have been documented in some individuals with HIV infection (e.g., Christeff et al., 
1988; Kumar et al., 1993; Villette et al., 1990), most studies have failed to find overt 
HP A abnormalities in the vast majority of individuals with HIV especially in individuals 
at early disease stages (e.g., Findling et al., 1994; Merenich et al., 1990). The association 
between higher serum cortisol levels and advanced disease progression (Findling et al., 
1994; Lortholary et al., 1996) may reflect dysregulation from mounting stressors and/or 
direct pathological consequences of the HIV virus or opportunistic infections on the 
endocrine/immune negative regulatory mechanism (refer to Figure 2). In the present 
sample, the estimated serum cortisol levels taken at a single tlme-point in the late
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morning to early afternoon fell within normal limits for most individuals (81%). 
Inclusion of more participants at advanced disease stages may increase the variability of 
cortisol levels within the sample. The potential subclinical dysregulation of the HPA axis 
in HIV infection may be better captured by measuring cortisol over the entire 24 hour 
cycle, as alterations may be more apparent at peak times early in the morning or trough 
times in the late evening. Given the broadly defined normal range of cortisol levels, 
measurement of disproportionate responses following experimental manipulations of the 
HPA axis (e.g., dexamethasone suppression, challenge with lipopolysaccharide, or 
presentation with psychological stressors) may provide a more effective means to 
examine individual alterations and their association with clinical symptoms in individuals 
with HTV infection.
Hypothesis 3. Contrary to previous investigations (e.g., Aukrust et al., 1994; 
Godfried et al., 1994; Kulinkovich et al., 1992), the serum and mRNA expression of 
proinflammatory cytokines were not directly associated with traditional biological 
indicators of disease status (i.e., lower CD4 T counts, higher CD8 T counts, and higher 
viral load). Given the possibility of more transient alterations in proinflammatory 
cytokine levels at early disease stages, single measures of biological indicators may be 
insufficient for tracking corresponding changes in immune functioning. The 
inflammatory cytokine cascades observed in typical immune responses to infection 
(Janeway & Travers, 1997) suggests that increased cytokine production may not directly 
accompany but, in fact, precede resultant immune cell alterations (e.g., cytokines trigger 
macrophage and CD4 T cell recruitment and stimulation, which may, in turn, enhance 
viral infection of immune cells and subsequent viral replication). Associations apparent in
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studies of individuals across disease stages may reflect the chronic elevations in 
proinflammatory cytokines with more advanced disease progression (Aukrust et al., 
1994; Godfried et al., 1994; Kulinkovich et al., 1992). Longitudinal studies sampling 
biological indicators across multiple time points may provide a means to further elucidate 
the exact nature of the relation between proinflammatory cytokines and disease 
progression in HIV.
On the other hand, reservoirs of the HIV virus contained within macrophages are 
thought to instigate the chronic low-grade activation and release of toxins from the host 
macrophage (Gendelman et al., 1994; Minagar et al., 2002). Hence serum neopterin 
levels, a general marker of macrophage activation and the extent of oxidative stress 
within the immune system, may be more directly correlated with recent measures of 
immune cell functioning (CD4 and CD8 cells) and viral replication (viral load). In the 
present study, elevated serum neopterin levels were associated with some of the 
traditional markers of disease progression (i.e., higher recent viral loads and lower recent 
CD4 T cell counts, but not correlated with elevations in recent CD8 T cell counts). This 
finding is consistent with a few previous investigations documenting elevated neopterin 
levels in many individuals at early disease stages and showing subsequent increases in 
neopterin levels with advanced disease status (e.g., Baier-Bitterlich et al., 1996; Fahey et 
al., 1990; Metha et al., 1996).
Interestingly, higher serum cortisol levels were also associated with lower CD4 T 
cell counts in the present sample. Lortholary and colleagues (1996) reported a similar 
finding in a study comparing cortisol levels in individuals across disease stages. Elevated 
cortisol levels may hasten progression of HIV infection by altering cellular metabolism
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(Brooke and Sapolsky, 2000) or by suppressing cell-mediated immunity and the 
production of Type 1 cytokines such as IL-2, IL-12, and IFN-gamma (Clerici et al., 1997; 
Rook et al., 1993; Sapse, 1997). A shift toward humoral immunity and elevated type 2 
cytokines (IL-4 and IL-10) may trigger destruction of CD4 T cells, reduce the efficacy of 
cytotoxic mechanisms at eliminating HIV-infected cells, and/or initiate a less effective 
means (i.e., antibody neutralization) to manage the HIV virus. This imbalance in type 1 
and type 2 expression has frequently been described in individuals with HIV infection 
especially at advanced disease stages (Clerici et al., 1997b; Fauci, 1996; Klein et al., 
1997; Salvaggio, Balotta, Galli, & Clerici, 1995) and has been associated with reduction 
in CD4 T cell counts, time to AIDS diagnosis, and time to death (Dolan et al., 1995; 
Luceyetal., 1991).
Hypotheses 4 and 5. This study also provided an opportunity to replicate research 
findings on the links between depression, fatigue, cognitive complaints, illness 
symptoms, and neuropsychological performance in an independent sample. Consistent 
with other studies, elevated depression scores were associated with increased fatigue 
(Millikin et al., 2003), endorsement of more illness symptoms (Carter et al., 2003), and 
higher subjective cognitive symptoms (e.g., Bassel et al. 2002; Beason-Hazen et al, 
1994; Hinkin et al., 1996; Moore et al., 1997; Rourke et al., 1999a). Total subjective 
cognitive complaints were also associated with fatigue (Millikin et al., 2003) and illness 
symptoms (Carter et al., 2003). While symptom measures were expected to be highly 
intercorrelated, neuropsychological performance was not expected to be associated with 
subjective symptoms of depression, fatigue, or medical illnesses based on previous null 
findings in large samples of individuals with HIV/AIDS (e.g., Carter et al., 2003; Millikin
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et al., 2003). Some selective studies have shown poorer performance in depressed 
patients as compared with normal controls on tests of attention (e.g., Landro, Stiles,& 
Sletvold, 2001; Williams et al., 2000), processing speed (e.g., Basso, Lowery, Neel, 
Purdie, & Bomstein), verbal recall (e.g., Fossati, Deweer, Raoux, & Allilaire, 1995; 
Ilsley, Moffoot, and O’Carroll, 1995), verbal fluency (e.g., Landro et al., 2001), and 
executive functioning (e.g., Ilonen et al., 2000). However, recent meta-analyses have 
challenged the conventional notion that neuropsychological deficits accompany major 
depression. When stringent methodological designs and only individuals with unipolar 
depression (i.e., no evidence of mania or psychoses) were considered, the analyses failed 
to provide support for consistent and substantial differences between depressed groups 
and normal controls (e.g., Burt, Zembar, & Niederehe, 1995; Veiel, 1997). Ahmad (2004) 
used rigorous cluster analytic techniques to further demonstrate that neither depressed 
children nor adults were differentiated from controls in terms o f their pattern of 
performance on a comprehensive neuropsychological test battery. Similarly, 
neuropsychological performance was not related to symptoms of depression, fatigue, or 
medical illnesses in the present sample.
As previously mentioned, self-reported cognitive symptoms and 
neuropsychological test performance sometimes do not directly correspond with each 
other in clinical practice. Some studies in samples of individuals with HIV infection have 
failed to find any association between subjective measures of cognitive difficulties in 
everyday situations and neuropsychological test performance (e.g., Minkin et a l, 1996; 
Moore et al., 1997; van Gorp et al., 1991), whereas other studies with broader ranges of 
cognitive symptoms assessed by the questionnaires and the inclusion of specific domains
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of neuropsychological functioning (in particular processing speed and working memory) 
have obtained modest but significant associations (e.g., Bassel et al., 2002; Mapou et al., 
1993; Rourke et al., 1999a). Given the modest effect size, the association between 
neuropsychological performance and subjective cognitive complaints observed in larger 
samples (e.g., Carter et al., 2003; Rourke et al., 1999a) was not apparent in this smaller 
sample of adults with HIV infection.
Clinical Implications and Directions for Future Research
Integration of approaches and dissemination of knowledge across research fields 
and disciplines is needed to better understand the variable manifestation of specific 
clinical symptoms in individuals with HIV/AIDS. This pilot investigation aimed to 
accomplish this by integrating biological studies on the neuropathogenesis of HIV within 
the broader clinical context by exploring potential biological correlates of commonly 
reported symptoms of cognitive impairments, depression, and chronic fatigue. The major 
findings were as follows: (1) neuropsychological impairment was not associated with 
serum levels of biological markers; (2) subjective symptoms, particularly the presence 
and severity of depressive symptoms, were related to some measures of immune 
activation (i.e., elevated neopterin and mRNA expression of IL-6); and (3) possible non­
responders to antidepressant treatment demonstrated elevated immune activation (i.e., 
higher mean serum neopterin levels in “non-responders” as compared with “responders”). 
While these preliminary findings require replication in a larger sample, they underscore 
the importance of considering multiple etiological factors when interpreting and 
managing clinical symptoms on an individual basis. Although the exact mechanisms 
underlying these associations cannot be derived from the current analyses, this study
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provides support for the role of biological processes (either on their own or as mediators 
of psychological factors) in the differential expression of clinical symptoms in HIV. 
More specifically, elevated serum neopterin levels (measured after the attainment of 
therapeutic drug concentrations) may serve to differentiate depressed individuals that are 
less likely to respond to antidepressant medications and consequently at greater risk of 
developing chronic depression.
The behavioural changes frequently accompanying chronic depression have 
significant implications at individual, clinical, and broader social levels. Chronic 
depression can adversely impact functioning in everyday life. Higher levels of comorbid 
fatigue, cognitive complaints, and general illness symptoms (e.g., headaches, pain, 
decreased appetite, and weight loss) in depressed individuals may further exacerbate their 
functional limitations. Some depressed individuals may not have the physical and mental 
stamina to sustain full-time employment. Financial constraints associated with disability 
status may place them in suboptimal living conditions. Deteriorations in physical health 
may also result from poor medication adherence or lifestyle changes (e.g., limited 
exercise, poor diet, or sleep disturbances). As depressed individuals often withdraw from 
social contacts, they are forced to face life’s challenges alone. Mounting psychological 
stress without supportive outlets may fuel depressive symptomatology. Alternatively, 
substance abuse or engagement in risky sexual behaviours may be used as a means to 
superficially cope with the depression and negative views of themselves or others. These 
practices can be particularly dangerous given their links to the transmission of HIY. 
Furthermore, depressed individuals may maximally utilize health care services in 
attempts to manage their psychological and physical discomfort. Clinicians may have
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difficulty detecting comorbid medical conditions as depressive symptoms may 
exaggerate certain illness symptoms while masking others. For example, routine 
screenings for depression, fatigue, and somatic symptoms need to be directly 
incorporated into neuropsychological assessments of individuals with HIV in order to 
assess the full significance of self-reported cognitive symptoms in everyday life.
Early identification of antidepressant-resistant patients (i.e., those individuals with 
elevated neopterin levels and depressive symptoms after a few weeks of treatment) would 
allow clinicians to design and implement alternative interventions (e.g. stress 
management techniques/ psychotherapy alone or in combination with drug therapies) 
aimed at alleviating their depressive symptoms and ultimately improving their quality of 
life. Given the widespread clinical and social implications of chronic depression, 
additional research exploring possible biological and psychological explanations for the 
differential response to antidepressants in this subgroup is warranted: Do these 
individuals have greater rates of drug metabolism, quicker degradation of 
neurotransmitters at synapses, or overstimulation of enzymes that regulate the production 
of neurotransmitters? Have these individuals suffered from longstanding depression (i.e., 
prior to their diagnosis of HIV)? Do they have a normal HPA axis response to stress or is 
their hormonal/immune system abnormal due to prolonged chronic stress? Can functional 
differences be observed in certain brain regions? Do they operate via specific coping 
strategies (e.g., avoidance or negative thinking) that are modifiable by cognitive 
behavioural therapy? Can psychosocial factors (e.g., social support) modify this 
interaction? Examination of biological factors pre- and post-interventions may also assist 
in monitoring the progress of susceptible individuals and may provide a better
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understanding of the characteristics that affect differential responses to antidepressant 
treatment Prospective research designs that examine the progression of symptoms and 
monitor biological changes at regular time intervals may be particularly fruitful in 
tracking the pattern of associations. To date, studies on antidepressant effects (including 
the present investigation) have been limited by confounding factors. Future research 
should attempt to control for the type of antidepressant (i.e., examining the effects of one 
antidepressant rather than a mixture of antidepressants) and the duration of treatment. As 
well, individual differences rather than group means may provide more insight into the 
characteristics of this subsample. During enrolment in the study, it will be important to 
define and carefully monitor potential biological changes in response to naturally 
occurring stressful transitions points during the course of HIV (e.g., diagnosis of HIV 
seropositive status, initiation of HAART, or diagnosis of AIDS) or in response to 
unpredictable life stressors (e.g., job loss, breakup of a close relationship, or death of a 
family member). Given that variations in the production and cyclic regulation of 
hormones exists between the sexes, attention should also be devoted to controlling for sex 
differences as well as daily, monthly, and seasonal variations. The collection of multiple 
samples over the course of the day or in response to experimental stimulation of the 
immune/HP A systems (e.g., lipopolysaccharide challenge, exposure to psychological 
stressors, or under dexamethasone suppression) may prove to be more sensitive measures 
of biological processes than the isolated serum samples used in the present study. While 
the preliminary findings with IL-6 mRNA expression and neopterin levels are intriguing, 
verification of these results in a larger follow-study is needed. Future investigations may 
wish to expand the psychoneuroimmunological framework to incorporate the role of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
neurotransmitters. Examination of neurotransmitter levels directly and indirectly through 
precursor or metabolite concentrations or the activity of enzymes responsible for its 
production and degradation would provide supplemental information about the possible 
biological mechanisms underlying symptom expression. Furthermore, advancements in 
functional imaging techniques may permit the direct evaluation of metabolism or 
neurotransmitter function within specific regions (e.g., hypothalamus, hippocampus, and 
prefrontal cortex) that contain higher densities of immune/endocrine receptors and have 
been proposed to mediate “illness behaviours.”
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APPENDIX A: Preliminary Analyses of HAART-stable participants 
Participants
Data was collected for fifteen individuals on a stable HAART regimen for at least 
1 Vi years (i.e., HAART-stable). Two individuals were removed from the analyses 
because they met one or more of the study exclusionary criteria (see pg. 48). 
Demographic data for the HAART-stable group are summarized in Table 14. The sample 
was comprised of all males. Participants were predominantly Caucasian (61%) with the 
majority reporting sexual contact (77%) as a major risk factor for HIV infection. Mean 
age, education, recent CD4, and recent CD8 were not different between the HAART- 
naive and HAART-stable groups. The groups differed in terms of mean lowest CD4 T 
cell counts [t (1, 39) = 2.69,p  < .01], recent viral load log {t (1,40) = 4.16, p  < .001], and 
estimated reading level [t (1, 40) = 2.05, p  < .05]. The distribution of individuals across 
CDC disease stages (CDC: Centers for Disease Control and Prevention, 1992) also 
differed between the HAART-naive and HAART-stable groups. Individuals in the 
HAART-stable group were at more advanced disease stages: none were asymptomatic 
(0%), 4 were mildly symptomatic (30%), and 9 had AIDS-defining illnesses or a nadir 
CD4 count of less than 200 (70%).
The means and standard deviations for the biological indicators, symptom 
measures, and neuropsychological deficit scores are presented in Table 15. The 
distribution across levels of impairment on the total and domain-specific 
neuropsychological deficit scores were similar within the HAART-naive and HAART- 
stable groups, though a greater proportion of individuals within the HAART-stable group 
demonstrated moderately to severely impaired performance on the learning efficiency
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
domain (compare Tables 7 and 16). This is farther reflected in a greater mean learning 
deficit for the HAART-stable as compared with the HAART-naive group [t (1, 42) = 
-1.98, p  < .05]. No differences were observed between the mean values on any other 
measures for the HAART-naive and HAART-stable groups (see Table 15).
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Table 14 '
Demographics for the HAART-stable sample (N =13)
Variables Mean (Standard Deviation)
Age (years) 39.8 (9.4)
Education (years) 13.5 (2.0)
WRAT reading (SS) 95.4 (8.9)
Recent CD8 Count 1123.2 (515.4)
Recent CD4 Count 412.5 (312.8)
Lowest CD4 Count 224.3 (226.2)
Recent Viral Load Log 2.1 (1.7)
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Table 15
Mean and standard deviations of the biological indicators, symptom measures, and
neuropsychological deficit scores in the HAART-stable sample (N =13)
Variables Mean (Standard Deviation)
TNF-alpha mRNA 828.6 (388.3)
IL-6 mRNA 164.3(131.9)
TNF-alpha Elisa " 7.6 (1.1)
IL-6 Elisa 0.6 (0.5)
Neopterin Elisa 7.3 (5.0)
Cortisol Elisa 339.5 (130.5)
BDI Cognitive-Affective5 7.6 (7.5)
Piper Fatigue Total1 3.3 (2.7)
PAOF Total1 38.9 (17.5)
PAOF Memory1 13.6(7.0)
Illness Total1 29.6 (16.8)
Total2 0.98 (0.7)
'y
Processing Speed 0.48 (0.7)
Working Memory/Attention 0.15(0.4)
Learning2 2.31 (1.3)
*Raw scores; 2Composite deficit ratings
Note. BDI = Beck Depression Inventory; PAOF = Patient Assessment 
of Own Functioning Questionnaire
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Table 16
Frequencies o f  individuals within impairment ranges across total and domain-specific













Average 3 (23) 9 (69) 11 (84) 3 (23)
Mild 7 (54) 3 (23) 2 (15) 4 (31)
Mild to Moderate 3 (23) 1 (8) 0 (0) 2 (15)
Moderate 0 (0) 0 (0) 0 (0) 3 (23)
Moderate to Severe 0 (0) 0 (0) 0 (0) 1 (8)
Severe 0 (0) 0 (0) 0 (0) 0 (0)
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Associations between biological indicators, symptom measures, and
neuropsychological performance
Spearman correlations were separately performed between the biological 
indicators, symptom measures, and neuropsychological deficit ratings for the HAART- 
stable group (see Table 17). However, the analyses are described in terms of interesting 
patterns rather than significant findings per se given the small sample size in = 13). For 
comparative purposes, individual subjects are plotted for each of the six biological 
indicators across total neuropsychological deficit scores (Figures 12 to 17). As shown in 
Figures 14 and 15, serum IL-6 (i.e., <11 pg/ml) and TNF-alpha concentrations (i.e., < 20 
pg/ml) were well within normal expectations for all individuals. With the exception of 
one or possibly two individuals, IL-6 and TNF-alpha mRNA expression were also tightly 
clustered (see Figure 12 and 13). This limited variability of these measures in the 
HAART-stable group makes it difficult to examine any relative differences across the 
symptom and neuropsychological measures. In contrast, there are a few cases above the 
clinical reference ranges for both serum neopterin (i.e., > 10 nmol/L) and cortisol (i.e., > 
375 nmol/L) (see Figures 16 and 17). Interestingly, all three participants with clinically 
elevated neopterin levels showed at least mild to moderate impairment on the total and 
learning efficiency deficit ratings. All three individuals with clinically elevated cortisol 
levels also demonstrated at least mild to moderate impairment on the total and learning 
efficiency domains. No consistent pattern was apparent for these individuals across the 
symptom measures.
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Table 17
Spearman correlations (r j showing the association o f the biological indicators and
measures o f  depression, fatigue, cognitive symptoms, and neuropsychological deficit













BDI Cog-Aff1 0.30 -0.36 0.02 0.37 0.35 -0.22
Piper Fatigue Total1 -0.03 0.22 0.16 -0.05 -0.29 -0.13
PAOF Total1 0.02 -0.18 -0.05 0.38 0.03 -0.32
PAOF Memory1 0.07 -0.61* -0.09 0.25 0.10 -0.27
Illness Total1 -0.02 0.02 0.03 0.26 -0.02 0.00
Total2 0.21 -0.16 0.25 0.25 0.48* 0.35
Processing Speed2 0.32 0.08 0.22 0.38 0.22 0.10
WM/Attn 0.00 0.19 -0.06 0.33 0.17 0.57*
Learning2 0.20 -0.28 0.21 0.15 0.48* 0.27
1Raw scores; 2Composite deficit ratings 
*p < .05 (1-tailed), **p< .01 (1-tailed)
Note. BDI Cog-Aff = Beck Depression Inventory Cognitive-Affective score; PAOF = 
Patient Assessment of Own Functioning Questionnaire; WM/Attn = Working Memory 
and Attention
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Figure 12. Scatterplot showing the relations between TNF-alpha mRNA expression and 
total neuropsychological deficit ratings in the FlAART-stable sample.
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Figure 13. Scatterplot showing the relations between IL-6 mRNA expression and total 
neuropsychological deficit ratings in the HAART-stable sample.
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Figure 14. Scatterplot showing the relations between serum TNF-alpha concentrations 
and total neuropsychological deficit ratings in the HAART-stable sample.
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Figure 15. Scatterplot showing the relations between serum IL-6 concentrations and total 
neuropsychological deficit ratings in the HAART-stable sample.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
114





Figure 16. Scatterplot showing the relations between serum neopterin concentrations and 
total neuropsychological deficit ratings in the HAART-stable sample.
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Figure 17. Scatterplot showing the relations between serum cortisol concentrations and 
total neuropsychological deficit ratings in the HAART-stable sample.
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